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ABSTRACT
Macrophages are pleiotropic cells capable of performing a broad spectrum of
functions. Their phenotypes are classified along a continuum between the extremes of
pro-inflammatory M1 macrophages and anti-inflammatory M2 macrophages. The
seemingly opposing functions of M1 and M2 macrophages must be tightly regulated for
an effective inflammatory response to foreign molecules or damaged tissue. Excessive
activation of either M1 or M2 macrophages contributes to the pathology of many
diseases. Infiltration of macrophages into breast tumors correlates with increased
metastasis and decreased patient survival. Tumors recruit macrophages to the primary site
as well as pre-metastatic niches, and educate them to adopt an M2-like phenotype,
thereby creating a growth-promoting immunosuppressive microenvironment. Emodin is a
Chinese herb-derived single compound and has shown potential to inhibit macrophage
activation and to prevent tumor growth. In this study, the effects of emodin on
macrophage response to M1 or M2 stimuli were investigated. Further, emodin was used
to treat mice bearing breast tumors and its effect on tumor cell-macrophage interactions
was examined. Emodin was found to bi-directionally tune the activation of macrophages
induced by LPS/IFNγ or IL4 through inhibiting NFkB/IRF5/STAT1 or IRF4/STAT6
signaling pathways respectively. Furthermore, emodin inhibited the removal of
H3K27m3 and the placement of H3K27ac histone modifications on genes associated with
macrophage activation. In mice bearing breast cancer, emodin treatment attenuated tumor
growth by reducing macrophage infiltration into the primary tumors and subsequent M2iv

like polarization. Reduced accumulation of M2-like macrophages in the tumors leads to
increased T cell activation and decreased angiogenesis. Emodin was shown to suppress
infiltration and M2-like polarization of TAMs by targeting the TAM-tumor interaction.
Emodin inhibited macrophage M2-like polarization in response to tumor cell secreted
molecules, inhibited tumor cell recruitment of macrophages through reducing CCL2 and
CSF1 expression, and block tumor cell-macrophage adhesion. In conclusion, our data
suggest that emodin is uniquely able to suppress excessive response of macrophages to
both M1 and M2 stimuli, and that emodin has potential as a new anti-breast cancer
therapy.
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CHAPTER 1
INTRODUCTION
1.1 MACROPHAGES AND THEIR PHENOTYPES
Macrophages are a heterogeneous population of innate immune cells that reside in
most tissues in the body (1,2). Tissue populations of macrophages were once thought to
be entirely derived from blood monocytes; however, recent research has shown that most
populations of macrophage originate from yoke sac precursors, with the exception of
those in the gastrointestinal tract (3-5). Under normal physiological conditions, tissue
populations are maintained through local proliferation without the need for monocyte
recruitment. Following injury or infection blood monocytes can be recruited to bolster the
local population; however, the role of tissue resident and monocyte derived macrophages
in different tissues is still under debate (6-9). Macrophages were first identified by their
ability to eat invading organisms, and initial research on macrophages was focused on
their functions in tissue defense. However, it has since been discovered that macrophages
also play substantial roles in normal tissue homeostasis as well as wound repair (10-12).
Macrophages are highly plastic cells which are constantly sampling their environment
and adapting their phenotype to the signals that they encounter. Macrophages display a
spectrum of phenotypes at either end of which are M1 macrophages and M2
macrophages which mirror the Th1/Th2 classification system of T cells (13-15). M1
macrophages are classical pro-inflammatory macrophages which support tissue defense.
M2 macrophages are non-classical “alternatively” activated cells which include a wide
1

range of phenotypes such as immune regulatory or tissue growth promoting. These
seemingly opposing functions of defense and repair need to be tightly regulated for a
proper response.
Macrophage polarization is regulated by a large number of transcriptional and
epigenetic signaling pathways which coordinate to fine tune the response to
environmental signals (14,16). Th1 cytokines (such as IFNγ and TNFα) and bacterial
products (such as LPS) induce macrophages to adopt a pro-inflammatory (M1) phenotype
characterized by the secretion of high amounts of inflammatory cytokines and reactive
oxygen and nitrogen species. IFNγ and TNFα activate the JAK/STAT cascade and lead
to STAT1 activation, while LPS activates the NFκB and MAPK cascade upon ligation
with TLR4. M1 macrophages can kill invading organisms through secretion of
proinflammatory mediators, phagocytic engulfment, or production of reactive species.
M1 macrophages also express costimulatory molecules and can activate CD4 + T cells. A
combination of stimuli including Th2 cytokines (such as IL4, IL10, and IL13), growth
factors (such as TGFβ, CSF1), glucocorticoids, and immune complexes, can polarize
macrophages toward an anti-inflammatory M2 phenotype (17). M2 macrophages have
major roles in tissue homeostasis and repair, inflammation resolution, and immune
regulation. M2 macrophages are characterized by high expression of Arg1, YM1, Mrc1,
and IL10, and low expression of pro-inflammatory cytokines (11). IL4/IL13 signal
through the common IL4ra receptor and lead to STAT6 phosphorylation and activation
which, along with several other secondary transcription factors, including IRF4, PPARγ
and KLF4, fine tune transcriptional responses in the cells (16,18-21). IRF4 induces the
M2 phenotype in response to parasite infections, and is regulated through the removal of
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H3K27m3 by the histone demethylase JMJD3 (22,23). Many of these signaling pathways
have shown to be antagonistic, which promotes the exclusive nature of the M1 and M2
phenotypes. STAT6 and STAT1 can competitively bind to the same DNA sequence to
inhibit each other (16,24). STAT6 can also inhibit NFκB DNA binding (25). IRF5 is
activated by TLR4 ligation and promotes the transcription of pro-inflammatory genes
(IL12b) while also suppressing the expression of anti-inflammatory genes (IL10) (16,26).
IRF4 competitively binds to MyD88 and is a negative regulator of IRF5 signaling (27).
Macrophage are also able to retain a memory for the signals that they have been exposed
to through epigenetic modification, which results in increased transcription (priming) or
repressed transcription (tolerance) upon future exposure (28-31). Cytokines cause the
addition of positive histone modifications H3K4m3 or H3K27ac to gene promoters which
lead to increased expression (32,33). The mechanisms of tolerance are incompletely
understood but could involve the loss of positive histone modifications and/or an increase
in negative histone modifications (such as H3K27m3) (31).
1.2 MACROPHAGES IN DISEASE
An imbalance in macrophage phenotypes has been shown to contribute to the
pathology of a large number of diseases (34-36).The same mechanisms by which M1
macrophages kill invading pathogens can also damage host cells. Excessive or chronic
M1 macrophage activation promotes tissue damage in neurodegenerative disorders,
arthritis, and autoimmune diseases (34,37,38). M1 macrophages are necessary to the
initial stages of the wound healing response to remove debris from the area; however,
prolonged M1 activation inhibits the healing of damaged tissue through excessive matrix
degradation and inhibition of tissue regeneration (39,40). Inflammatory mediators
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released from M1 macrophages inhibit the secretion of ECM proteins and increase the
secretion of proteases. This effect has been seen in many pathologies including
ischemia/reperfusion injury in the myocardium, diabetic chronic wounds, and central
nervous

system

injuries

(37,39,41,42).

Further,

increased

inflammatory

monocyte/macrophage infiltration has been shown to correlate with disease severity in
patients with myocardial infarction, atherosclerosis, and metabolic disorders (43-46).
Chronic M1 activation has also been shown to promote the development of cancer
(34,47,48) through creating mutagenic environments. Patients with inflammatory bowel
disease or chronic lung inflammation, caused by infections or particulate inhalation, have
been shown to have greatly increased risks for colon or lung cancer respectively (49,50).
Shifting the balance toward M2 macrophages has been shown to be beneficial in some
experimental models; however, prolonged or excessive M2 macrophage activation can
also be detrimental.
M2 macrophages contribute to allergic inflammation and lung damage through
the secretion of Th2 cytokines IL4 and IL13, (35,36), and the recruitment of eosinophils
(51). Macrophages have also been shown to impair functions of many organs including
the lungs, liver, and pancreas through promoting fibrosis (52). M2 macrophages can
indirectly increase ECM deposition by recruiting fibroblasts and inducing them to
become myofibroblasts through secretion of growth factors TGF-β and PDGF and can
directly regulate ECM turnover through production of MMPs and TIMPs (53). Further,
M2 macrophage infiltration correlates with increased cancer growth and metastasis in
multiple types of cancer (36,54). While M1 macrophages have been shown to promote
tumor initiation, as tumors develop, tumor associated macrophages (TAMs) are educated
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to adopt a pro-tumor M2-like phenotype (55). Macrophages are the largest population of
tumor infiltrating immune cells in many solid tumors (56). Tumor cells recruit and
educate macrophages toward an M2-like phenotype through secretion of soluble
mediators (such as CSF1, CCL2, IL10, and TGFβ), and through direct cell-cell
interactions (57-59). TAMs in turn create a niche to support tumor stem cells growth and
survival (60). TAMs protect tumors from immune response through secreting antiinflammatory cytokines (such as IL10) and the depletion of metabolites (through Arg1
and iNOS) (61,62). Further, TAMs promote angiogenesis through secreting VEGF and
proteases (MMPs) to remodel the extra cellular matrix (63,64). TAMs also promote
tumor cell migration toward blood vessels and intravasation (65). Macrophages at distant
sites have also been shown to be trained by signals released from the primary tumor to
create environments receptive to circulating tumor cells termed pre-“metastatic
niche”(66). These macrophages support tumor cell extravasation and colonization of the
tissue through remodeling the ECM and promoting angiogenesis.
Many strategies have been developed to target macrophage-driven inflammation
in experimental disease models including: macrophage recruitment, survival, and
activation. However, translating therapies from experimental models to clinical settings
has had mixed results. Inhibiting macrophage recruitment to tumors through blocking
CCL2/CCR2 signaling has shown great potential in pre-clinical studies and has advanced
to clinical studies for treatment of bone metastasis and pancreatic cancer (67). Similarly,
inhibition of macrophage adhesion molecules (CD11/CD18) reduced macrophage
infiltration into the myocardium post MI and improved healing in animal models;
however, it was not effective in clinical trials (68). Monoclonal antibodies have been
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developed to block macrophage activation by targeting cytokines/chemokines (or their
receptors) such as TNFα and IL1. Anti-TNFα therapy has shown to be effective in
treating arthritis, but not other inflammatory conditions including multiple sclerosis and
I/R injury (69). Targeting the CSF1 axis has shown strong potential in cancer treatment.
CSF1/r1 inhibition greatly decreased macrophage infiltration into mouse mammary
tumors which led to an increase T cell response (70). CSFr1 also sensitized pancreatic
tumors to T cell check point blockade (71). Inhibition of macrophage activation by
HDAC inhibitors has also shown therapeutic potential for a variety of inflammatory
diseases and cancers (72,73).
There have been many challenges in developing macrophage-targeting therapies
for clinical use (69). If treatment is administered too late during the disease, irreversible
tissue damage can occur; therefore, targeting the macrophage/inflammatory component
of disease would likely require chronic therapies to be administered early during disease
progression. Further, most current treatments target one molecule or pathway, but there
are many redundant and compensatory pathways built into the inflammatory responses.
Therefore, there is much interest in herb derived compounds since they can modulate
multiple inflammatory pathways, are inexpensive, and have low toxicity for chronic
treatment (74). Many compounds have shown potential to inhibit macrophage activation;
however, experimental studies with these compounds has focused on responses to stimuli
which induce a narrow range of activation (either M1 or M2 phenotypes but not both)
(74-77). A compound which could inhibit a broad range of macrophage phenotypes
through regulation of multiple signaling pathways would have great clinical potential.

6

1.3 MACROPHAGES AND CANCER
M1 macrophages have been shown to promote tumor initiation by contributing to
chronic inflammation. Approximately 25% of cancers are related to chronic infections
and inflammation (49). However, as tumors grow the phenotype of macrophages
switches toward a M2-like tissue growth-promoting phenotype (47,55). Tumor cells
recruit and educate macrophages toward a M2-like phenotype through secreting a
spectrum of chemokines and cytokines (with CCL2 and CSF1 being two of the most
important (59)), through direct cell-cell interactions, and through the creation of a
hypoxic microenvironment (57,78-80). Tumor signals trigger M2-like phenotype through
activating multiple signaling pathways including STAT1, 3, and 6, C/EBPβ, PPARγ, and
IRF4 (55,81-84). Macrophages in turn secrete growth factors (such as EGF and VEGF)
which promote tumor cell growth and migration toward and into blood vessels, promote
angiogenesis, and inhibit immune response (65,85). TAMs generally express high levels
of scavenger, mannose, and galactose receptors; low levels of co-stimulatory molecules,
and their metabolism is shifted to ornithine and polyamine production (67).
M1 macrophages have the potential to inhibit tumor growth and help mediate the
effectiveness of immunotherapies. Infiltration of M1 macrophages has been correlated
with a favorable prognosis in numerous cancers, including colon, cervical, and lung
cancer (86-88). Macrophage cytotoxicity toward cancer cells has been known for nearly
four decades. Tagliabue and colleagues found that adherent phagocytic cells isolated
from the peripheral blood or the peritoneal cavity of mice were selectively able to kill
tumor cells (89). These cells were specifically identified as macrophages and not natural
killer cells. Similarly Urban et al. showed that activated macrophages were able to
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directly kill tumor cells in a TNFα dependent manner (90). More recent studies have
shown the therapeutic benefit of activating tumor associated macrophages toward an M1
phenotype. Stimulating macrophages with tumor cell lysate enhanced their expression of
co-stimulatory molecules (91). Vaccination of mice with these macrophages attenuated
tumor growth and increased T cell activation. Guiducci and colleagues reported that
adenoviral delivery of chemoattractant CCL16 and activation of macrophages with CpG
and an IL10 receptor antagonistic antibody shifted TAM phenotype toward M1 and led to
rapid de-bulking of breast and colon tumors in mice (92). Tumor regression was
dependent on direct killing of tumor cells by macrophages and activation of T cells by
dendritic cells. Many experimental studies have demonstrated similar results, revealing
that tumor regression requires the interplay between M1 macrophages and T cells. In
myeloma models, Th1 stimulated macrophages are necessary for the killing of tumor
cells (93). Furthermore, M1 macrophages have been shown to play a major role in the
effectiveness of immunotherapies. Injection of tumor bearing mice with a synthetic
vaccine led to tumor regression which was dependent on recruitment and activated of M1
macrophages by CD8+ T cells (94). Similarly, macrophages have been shown to mediate
tumor killing following monoclonal antibody therapy (95-97).
However, in spite of macrophage’s natural cytotoxic potential, macrophage
infiltration into tumors is most often associated with worse clinical outcomes. Over 80%
of immunohistochemical studies performed on human tumors have shown that increased
TAM infiltration is associated with worse clinical prognosis (98). This is likely because
the majority of TAM’s adopt a pro-tumor M2-like phenotype (98). Particularly in breast
cancer, studies have shown that macrophage infiltration and M2-like polarization are
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associated with increased angiogenesis and metastasis and reduced survival (54,99,100).
Macrophage chemoattractant MCP1/CCL2 has been correlated with increased TAM
infiltration and was a significant indicator in early relapse (101). DeNardo and colleagues
revealed that there was an inverse association between CD68+ macrophages and CD8+ T
lymphocytes in human breast cancer tissues and that there was increased macrophage
infiltration into the tumors from patients who had received neoadjuvant chemotherapy
compared to those treated with surgery alone (102). Further, the ratio of CD68+ to CD8+
cells predicted patient response to neoadjuvant chemotherapy.
TAMs are essential to breast cancer pathogenesis. TAMs have been reported to
comprise up to 80% of infiltrating leukocytes in late stage mouse mammary tumors (56).
TAMs are necessary for immune suppression, angiogenesis, ECM remodeling and tumor
cell migration and metastasis. Resident macrophages support stem cell activity in the
mammary glands and their depletion from mammary fat pads prevents stem cell
repopulation of de-epithelialized mammary glands (103). Similarly macrophages also
support the growth of breast cancer stem cells through juxtacrine signaling; macrophage
depletion is able to almost completely block tumor initiation following implantation of
cancer stem cells into the mammary fat pad (60). Infiltration of macrophages into breast
tumors depends on CSF1 signaling, and overexpression of the macrophage of CSF-1 and
its receptor (CSF-1R) in macrophages correlates with poor prognosis in humans (67). In
experimental models of breast cancer, genetic overexpression or inhibition of CSF1 led to
increased or decreased macrophage infiltration, respectively, and concomitantly led to
exacerbated or attenuated tumor growth (104). Similarly, blocking CCL2 signaling
resulted in significantly reduced macrophage infiltration and tumor size, although
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cessation of treatment resulted in a rebound with increased macrophage infiltration and
tumor growth (102). Co-injection of M2 macrophages with tumor cells into the mammary
fat pad significantly increased tumor growth (105). In agreement with these findings,
Galmbacher and colleagues treated mice which had breast cancer with an attenuated
strain of Shigella flexneri which selectively killed macrophages (106), and found that a
single injection with S. flexneri resulted in complete regression of tumors. Similarly,
tumor cell migration and intravasation have been shown to be dependent on TAM
signaling (107). Further, pre-clinical studies have shown that inhibition of TAM’s
immune suppressive phenotype, without changing the overall number of TAMs or
vascularity of tumors, is sufficient to reduce breast cancer growth (108). TAMs have also
been shown to promote chemotherapy resistance, and can support tumor relapse
following radiotherapy (109,110).
The dependence of breast tumors on macrophages makes TAMs a strong
therapeutic target, and several strategies for targeting TAMs have been developed
including: inhibition of recruitment, M2-like activation, survival, and polarization
(67,111). Many of these therapies have advanced to clinical trials. Among the most
promising treatments is blocking CSF1 signaling through inhibiting CSFr1. Interfering
with the CSF1/r1 axis has been shown to inhibit macrophage recruitment and TAM
activation in many preclinical studies. CSF1/r1 inhibition greatly decreased macrophage
infiltration into mouse mammary tumors which led to an increase T cell response (70).
CSFr1 also sensitized pancreatic tumors to T cell check point blockade (71). CSF1
inhibition also could sensitize tumors to other therapies. Clinical trials are also being
performed on inhibition of CCL2 signaling which can potently block macrophage
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recruitment (67). Another promising strategy is re-polarizing TAMs towards an antitumor M1 phenotype. CD40 agonists are able to induce macrophages toward tumor-lytic
phenotypes and can promote the development of T-cell–dependent antitumor immunity
(112,113). CD40 agonists are showing promising clinical activity and can increase the
survival of melanoma patients. Similarly anti-CD47 antibodies, which bind to CD47 a
“don’t eat me signal” on tumor cells, are able to improve macrophage phagocytosis and
the priming of T cells and are showing encouraging results in clinic trials (114).
Zoledronic acid is a compound which has shown selective toxicity for macrophages
(115). Pre-clinical studies have shown that ZA can inhibit spontaneous mammary
cancerogenesis by reducing the number of TAMs (116,117). A phase 3 clinical trial has
shown that ZA treatment could improve disease free survival in premenopausal patients
with estrogen-responsive early breast cancer when added to adjuvant endocrine therapy
(118,119).
1.4 EMODIN AND INFLAMMATORY DISEASE
Natural compounds and their derivatives comprise the main source of new drugs
(120). Herb derived compounds provide many benefits over purely synthetic structures.
Their potential toxicity is often better known, especially in compounds isolated from
traditional medicine (121). Further, natural products are more frequently found to bind to
clinical targets than synthetic compounds since they more closely resemble natural
ligands or metabolites found in human cells (121-123). Recently, increasing numbers of
compounds have been purified from traditional medicines and shown to have biological
activity. Chinese traditional medicine, which has demonstrated efficacy in patients for
thousands of years, is a particularly rich source of potential new therapies (120,124). One
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of the main obstacles preventing the development of many herb derived compounds into
modern drugs is the lack of information on their distinct mode of action (121).
Emodin is a trihydroxy-anthraquinone (Figure 1.1) and is the active ingredient of
several Chinese herbs including Chinese rhubarb and has been used to treat a variety of
inflammatory diseases (125). Emodin has generated much interest because of its strong
anti-inflammatory and anti-cancer properties as well as its low cost and low toxicity.
Prior studies performed on emodin hint at its potential to be a broad acting regulator of
macrophage activation. The NIH’s National Toxicity Program (NTP) performed an indepth evaluation of emodin’s toxicity by administering emodin in the feed of rats and
mice for up to two years (126). There was no effect on survival of the animals even at
doses up to 1000 mg/kg/day for rats and 70 mg/kg/day for mice. Further, emodin showed
little to no evidence of carcinogenic activity. Emodin has low water solubility and is
cleared from the blood stream fairly quickly. The NTP study found that emodin had a
half life of about 23 min in mice following a single dose (10 mg/kg) intravenous
injection. Our lab has found that one hour following a single intraperitoneal injection of
emodin (40 mg/kg) the serum concentration of emodin (including its conjugated forms) is
just under 30 µM, but by 24 hour the serum concentration is almost undetectable (Figure
1.2).
Emodin has a strong potential to target the macrophage component in many
diseases. Excessive M1 macrophage activation causes tissue damages and exacerbates
numerous pathologies. Emodin has been shown to attenuate inflammation and reduce the
severity of many experimental disease models including arthritis, hepatic steatosis,
atherosclerosis, myocarditis, pancreatitis, and cancer (125). Hwang et. al. reported that IP
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administration of emodin (10 mg/kg) inhibited joint destruction in a mouse model of
arthritis (127). Emodin decreased TNFα and IL1β levels in the serum and joint by
decreasing NFκB signaling. Similarly Wu et. al. found that emodin treatment dose
dependently attenuated myocardial damage following coronary artery occlusion in mice
(128). Emodin decreased NFκB activation in the myocardium which led to decreased
TNF-α expression. Emodin treatment significantly inhibited tissue damage in numerous
acute inflammatory models including LPS induced Kidney and Lung inflammation
through decreasing the production of inflammatory cytokines (TNFα, IL1β, and IL6) and
the infiltration of inflammatory cells (129,130). Emodin decreased inflammatory cell
infiltration and LPS induced activation of NFκB signaling. Our lab and others have
shown that emodin can protect the liver from injury from numerous different
inflammatory insults. Liu et. al treated ethanol fed mice with emodin (50 mg/kg
administered by oral gavage) and found that emodin improved liver function and
decreased hepatic oxidative stress (131). Orally delivered emodin was also able to protect
mice from concavalin A induced T cell-mediated hepatitis (132). Emodin substantially
reduced hepatic expression of pro-inflammatory cytokines and chemokines (TNFα, IFNγ,
IL1β, IL-6, IL-12, iNOS, ITGAM, CCL2, MIP-2 and CXCR2) and dramatically reduced
the number of hepatic infiltrating T cells and macrophages through blocking NFκB and
P38 signaling. Our lab found that IP administered emodin attenuated systemic and
hepatic inflammation in high fat diet fed mice administered with LPS (133). Emodin
significantly reduced macrophage infiltration into the liver, and mechanistic studies
revealed that emodin inhibited P38 and ERK phosphorylation in LPS treated
macrophages.
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In spite of the many model systems which have been used to study emodin’s
therapeutic potential, the detailed molecular mechanisms of emodin’s benefits have not
been fully elucidated; however, emodin has been shown to target a variety of signaling
pathways in different cell populations. Emodin has been described as a promiscuous
kinase inhibitor (134). Yang et. al. revealed that emodin could induce the differentiation
of fibroblasts to adipocytes by binding to and activating PPARγ (135). Emodin was also
able to inhibit inflammatory cytokine release by hypertrophic scar fibroblasts through
blocking PI3K and AKT phosphorylation (136). In synoviocytes, emodin inhibited LPSinduced activation by reducing HDAC1 expression and activity but had no effect on
NFκB or Erk signaling (137). However, emodin has been shown to inhibit NFκB nuclear
translocation and DNA binding in endothelial cells through blocking IkB degradation
(138). Emodin is also able to inhibit NFκB signaling induced by IgE in mast cells along
with mobilization of intracellular Ca2+ and activation of the mitogen-activated protein
kinase and phosphatidylinositol 3-kinase (PI3K) pathways through blocking the
phosphorylation of Syk (139). Further, emodin has been shown to be a potent regulator of
macrophage activation in numerous different animal models by blocking NFκB and MAP
kinase signaling as well as inhibiting the NRLP3 inflammasome (125,140).
Macrophages are plastic cells capable of displaying a large number of different
phenotypes. However, studies with emodin haven been focused on response to stimuli
which induce a narrow range of activation (either M1 or M2 phenotypes but not both).
Evidence does exist, however, which hints that emodin might be able to inhibit a broad
spectrum of phenotypes depending on the environment of the cells. Emodin has already
been shown to suppress M1 macrophage activation and push Th1 inflammation to Th2 by
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decreasing the expression of IL1, iNOS, TNF, IFN and IL12 and increasing the
expression of TGFβ, IL4, IL10, and PPARγ (74,131,141-144). In other studies, however,
emodin has decreased Th2 inflammatory mediators and increased Th1. Chu et. al showed
that emodin could attenuate Th2 driven hyper-responsiveness in the lungs of mice
sensitized and challenged with OVA (145). Emodin substantially decreased BALF levels
of IL4, IL5, and IL13 and suppressed the number of infiltrating macrophages. Other
studies have shown that emodin is able to inhibit PPARγ and TGFβ expression (146,147).
Recently, our lab has shown that emodin could inhibit breast cancer metastasis through
blocking infiltration of M2-like macrophages (148).
1.5 EMODIN AND CANCER
There is increasing interest in using herb derived compounds to complement
modern therapies by modulating the inflammatory component of tumors. Emodin’s
ability to regulate macrophage activation makes it a strong candidate as therapy for breast
cancer. Emodin treatments have shown benefits in many different pre-clinical animal
models, including cancers of the gastric system, respiratory system, reproductive system,
and blood system, and emodin has been shown to repress tumor growth in many clinical
situations (125,149). The vast majority of these studies have focused on emodin’s direct
effects on tumor cells; however, the detailed mechanisms have not been fully elucidated.
Various different mechanisms have been proposed for emodin’s anti-tumor properties in
different tumor types. Emodin has been shown to inhibit DNA repair enzymes, induce
ROS generation, and inhibit NFκB, ERK 1/2, p38, JUNK and PI3K/AKT signaling
pathways in different cell lines (125). Emodin has been reported to trigger apoptosis in
both caspase dependent and independent manners (150-152). In many cancer cell lines,
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emodin induced apoptosis by increasing ROS production (150,153,154). Emodin has also
been shown to inhibit NFκB signaling in a wide variety of cancer cells (152,153,155157). Emodin inhibited myeloma growth by blocking JAK2 activation and the subsequent
activation of STAT3, but had no effect on the phosphorylation of AKT, ERK 1/2, or P38
(158). However, emodin was shown to inhibit ERK 1/2 signaling in human non-small
cell lung cancer cells and sensitize them to EGFR inhibitor gefitinib (159). Emodin also
inhibited ERK 1/2 activity in MDA-MB-231 and reduced their migration (160). Emodin
can induce apoptosis in HER2/neu breast cancer cell lines by inhibiting HER2/neu
tyrosine kinase (161,162). Huang et. al. reported that emodin induced apoptosis in Bcap37 breast cancer cells by decreasing the Bcl-2/Bax ratio and increasing cytoplasm
cytochrome c (163). MCF-7/Adr breast cancer cells are resistant to Adriamycin and
cisplatin. Emodin treatment can reverse drug resistance in MCF-7 cells by down-regulate
the expression of DNA repair protein ERCC1 (164). However, for many tumor cells
emodin is only cytotoxic at high doses, which can be difficult to achieve in vivo.
In spite of emodin’s demonstrated anti-inflammatory properties, most studies with
emodin have taken a narrow approach in determining emodin’s mechanisms and have
focused only on emodin’s direct effects on tumor cells. However, a few studies have
found that emodin is able to attenuate tumor growth by modulating the tumor
microenvironment. Recently, emodin was found to inhibit pancreatic cancer growth by
targeting both the tumor cells and the microenvironment (165). Emodin was able to
reduce angiogenesis by inhibiting NFκB signaling, and its regulated factors VEGF,
MMP-2, MMP-9, and eNOS. MMP2 and 9 promote tumor angiogenesis by cleavage of
ECM proteins (166). Emodin is able to inhibit MM2/9 secretion from colon cancer cells
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possibly by blocking VEGFR signaling (167). Emodin has also been shown to inhibit
MMP9 production in breast cancer and tongue cancer (160,168). Further, emodin has
been reported to directly inhibit angiogenesis by attenuating endothelial cell proliferation,
migration and tube formation through blocking VEGF-A receptor-2 (KDR/Flk-1)
signaling and downstream effector molecules, including focal adhesion kinase, Erk 1/2,
p38 mitogen-, Akt and eNOS (169,170). Our lab was the first to show that emodin
treatment could inhibit tumor growth by targeting macrophages (148). Emodin treatment
of mice bearing established breast tumors inhibited pulmonary metastasis by reducing
infiltration of M2-like macrophages into the lungs of the mice. Mechanistic studies
showed that emodin inhibited macrophage migration toward tumor cell derived factors,
and blocked M2-like polarization by inhibiting C/EBPβ and STAT6 signaling. However,
emodin had no effect on the growth of the established primary breast tumors. Emodin’s
ability to target both cancer cells and macrophages confers it good potential as a therapy
to inhibit tumor cell-macrophage signaling loop which supports the tumor promoting
microenvironment. Therefore, for this study I will comprehensively study emodin’s
effects on macrophage activation and investigate its therapeutic potential for breast
cancer treatment.
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Adapted from Jia et al (133).
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CHAPTER 2
EMODIN IS A BIDIRECTIONAL MODULATOR OF
MACROPHAGE ACTIVATION.
2.1 BACKGROUND
The diversity of macrophage phenotypes presents a major obstacle to the
development of macrophage targeted therapies. There is much interest in using herb
derived compounds to inhibit macrophage activation since they can modulate multiple
inflammatory pathways, are inexpensive, and have low toxicity for chronic treatment
(74). However, experimental studies with these compounds haven been focused on
responses to stimuli which induce a narrow range of activation (either M1 or M2
phenotypes but not both) (74-77). A compound which could inhibit a broad range of
macrophage phenotypes through regulation of multiple signaling pathways would have
great clinical potential. Studies in our lab and others have shown that emodin has
potential to regulate both Th1 and Th2 driven inflammation (133,145,148,171), which
indicates that emodin is able to regulate a broad spectrum of macrophage phenotypes.
However, emodin’s mechanism has not been fully discovered.
Therefore, we tested the ability of emodin to regulate both M1 and M2
macrophage activation in order to comprehensively characterize emodin’s effects on
macrophages and attempt to elucidate its mechanism of action. Primary mouse
macrophages were stimulated with LPS/IFNγ as an M1 stimulus or IL4 as a M2 stimulus
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and emodin’s mechanism of action was investigated using a whole genome microarray.
Emodin was able to inhibit the change in expression of a large percentage of both M1 and
M2 associated genes. Emodin inhibited the NFkB, IRF5 and STAT1 pathways following
LPS and IFNγ stimulation and the STAT6 and IRF4 signaling pathways following IL4
stimulation. Finally our data showed for the first time that emodin is able to regulate
macrophage memory by inhibiting changes in H3K27m3 and H3K27ac at the promoter
regions of several key genes. Taken together, our data shows that emodin has the ability
to bi-directionally modulate macrophage activation by targeting multiple pathways.
2.2 DETAILED METHODS
Peritoneal Macrophage isolation and culture—
Primary macrophages were collected from the peritoneal cavity of mice. Three
milliliters of 4% Thioglycolate (Hi media Laboratories Ltd; Mumbai, India) solution was
injected intraperitoneally into 8-12 week old C57BL/6 mice. Three days later,
macrophages were collected by lavaging the peritoneal cavity with 20 mls of PBS. The
cells were then resuspended in high-glucose Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen, Grand Island, NY) containing 10% fetal bovine serum (FBS), 100
U/mL penicillin (Sigma-Aldrich, St. Louis, MO), and 100 μg/mL streptomycin (SigmaAldrich) and seeded into culture plates. They were cultured at 37 ᵒC in a humidified CO2
incubator for 2 h, and then non-adherent cells were washed away with PBS and the
macrophages were cultured overnight in serum free DMEM containing penicillin and
streptomycin. The macrophages were then treated with DMEM containing IL4 (10 ng/ml,
BioAbChem Inc. Ladson, SC) or LPS (100 ng/ml, Sigma-Aldrich) and IFNγ (20 ng/ml,
BioAbChem Inc) with or without emodin. Emodin was purchase from Nanjing Langze
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Medicine and Technology Co. Ltd (Nanjing, China) and verified by NMR spectroscopy
and mass spectrometry as we previously described (28). Emodin was dissolved in DMSO
at a concentration of 10 mg/ml.
For macrophage memory experiments, macrophages were stimulated overnight
with IL4 or IFNγ with or without emodin. Then the cells were washed 3x with PBS and
cultured for 2 or 5 days in DMEM with 2% FBS. The media were changed every 2 days.
The cells were then restimulated with IL4 or LPS for 6 h.
Microarray analysis—
Microarray analysis was carried out as described previously (172), with a few
alterations. Macrophages were stimulated with IL4 for 6 h or LPS+IFNγ for 24 h with or
without emodin (50 µM). Samples were prepared in biological replicates of 4. Cells were
lysed with Qiazol and RNA was extracted using Qiagen’s miRNeasy kit. Next Agilent’s
2100 Bioanalyzer was used to determine the quality and quantity of the RNA. All RNA
samples had a RIN of 9.2 or higher. The RNA was amplified and labeled with Agilent’s
Low Input Quick Amp Labeling Kit (Agilent) according to the manufacturer’s
instructions. Labeled RNA was then purified using Qiagen’s RNeasy Mini Kit (Qiagen,
Valencia, CA) and dye incorporation and cRNA yield were assessed. Labeled samples
were hybridized to Agilent Whole Mouse Genome Microarrays 8x60K (Agilent) using
Agilent’s Gene Expression Hybridization Kit (Agilent) according to the manufacturer’s
instructions. Microarray analysis was performed using an Agilent DNA Microarray
Scanner System (Cat. #G2565CA). A heatmap of genes from relevant pathways
identified by Ingenuity pathway analysis was generated using R function heatmap.2. A
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principle component analysis was performed using all genes differentially expressed in at
least one of the treatment groups using the R function prcomp.
Phagocytosis assay—
Macrophages were seeded into a 96-well plate (2x105 cells/well) and were
stimulated with IL4 or LPS+IFNγ for 24 h with or without emodin. Then phagocytotic
activity was measured using a Vybrant Phagocytosis assay kit (Molecular Probes). The
medium was removed and the cells were washed with PBS. The fluorescent BioParticle
suspension was added to the cells and incubated up to 6 h. After the indicated time, the
BioParticle suspension was removed and any extracellular fluorescence was quenched
with trypan blue. The intracellular fluorescence was then detected using a Spectramax
M5 microplate reader (Molecular Devices, Sunnyvale, CA).
Macrophage migration assay—
Macrophages were stimulated with IL4 or LPS+IFNγ for 24 h with or without
emodin. The media was then removed and the cells were washed with PBS. The cells
were then resuspended in DMEM with scraping and 2x10 5 macrophages were seeded in
triplicate into the top chamber of transwell inserts with 8 μm pores (Corning) and placed
in 24 well plates. Serum free DMEM with 20 ng/ml MCP1 (BioAbChem Inc, Ladson,
SC) was placed in the bottom of the wells. After 4 h, inserts were fixed in 4%
paraformaldehyde for 20 min; the cells in upper inserts were swabbed using cotton buds,
and the cells left on the membrane were stained with DAPI (5 μg/ml) for 1 min. The
inserts were then cut out, mounted onto slides and imaged under a Nikon Eclipse NI-U
fluorescence microscope (Nikon Inc. Melville, NY) at

20 × magnification (5

fields/insert). DAPI stained cells were quantified using Nikon NIS-Elements software.
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NO production assay—
Macrophages were stimulated with LPS+IFNγ for 24 h with various
concentrations of emodin (0-50 µM) in triplicate. The culture media was then collected
and the NO content was detected using a Griess assay performed with a Nitrite/Nitrate
colormetric kit (Sigma-Aldrich) according to the manufacturer’s instructions. Briefly, the
supernatant was centrifuged at 1000xg for 15 minutes to remove any cells. Then 80 µl of
sample was placed in a 96 well plate and 50 µl of Greiss reagent A was added to the
samples and incubated for 5 minutes. Then 50 µl of Greiss reagent B was added to the
samples and incubated for 10 min. The assay was read using a Spectramax M5
microplate reader (Molecular Devices, Sunnyvale, CA) at 540 nm.
Western blotting and Real time PCR—
Following stimulation with IL4 or LPS+IFNγ with or without emodin for varying
periods, macrophages were lysed with cell signaling lysis buffer (Millipore) in order to
collect protein from whole cell lysates. The cells were incubated in lysis buffer for 20
min on ice, then mechanically homogenized and collected. In order to examine nuclear
factor translocation, cytoplasmic and nuclear extracts were prepared using the Epiquik
Nuclear Extraction kit (Epigentek, Farmingdale, NY). Macrophages were washed with
PBS following treatment and collected by scraping. Then the cells were incubated in lysis
buffer 1 for 15 min. The nuclei were pelleted by centrifugation at 2000xg for 5 min and
the supernatant containing cytoplasmic proteins was collected. The nuclei were
resuspended in nuclear lysis buffer. The cells were incubated for 15 minutes, and then
sonicated using a Diagnode Bioruptor Pico for 3 cycles of 30 s on/30 s off. The samples
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were centrifuged again for 10 minutes at 20,000xg and the supernatant was placed in a
new tube.
In order to detect genome wide levels of histone H3 modifications, histones were
isolated from macrophages using EpiQuik total histone extraction kits (Epigentek,
Farmingdale, NY) according to the manufacturer’s directions. Briefly, macrophages were
washed with PBS following treatments and collected by scraping. Macrophages were
resuspended in pre-lysis buffer and incubated on ice for 10 min. The nuclei was then
pelleted by centrifugation and resuspended in approximately 40µl lysis buffer and
incubated on ice for 30 min. The lysate was centrifuged at 20,000xg for 5 min and the
supernatant was collected. The lysate was then neutralized with balance buffer.
Total protein in the lysates was quantified using a BioRad colormetric DC Protein
Assay (Bio-Rad Laboratories, Hercules, California). Total protein (40-50 µg for whole
cell lysates, 40 µg for cytoplasmic lysates, 20-30 μg for nuclear lysates, and 10-15 µg for
histone extracts)

was separated on 4-20% Tris-glycine pre-cast gels (Pierce) and

transferred onto Nitrocellulose membranes (Bio-Rad Life Science, Hercules, CA).
Antibodies are shown in table 2.1. The membranes were then probed with HRP
conjugated secondary antibodies (Table 2.1), and signals were detected using Pierce ECL
Western Blotting Substrate (Pierce). For a loading control, nuclear fraction blots were
stained with Ponceau S (0.5% (w/v) Ponceau S in 1% (v/v) acetic acid) and destained
with water. Densitometry analysis was performed using Image Studio Lite version 5.0
(LiCOR Biosciences).
For qPCR, macrophages were washed with PBS following treatments, then lysed
with Qiazol. RNA was extracted using Zymo research Direct-zol RNA isolation kit.
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cDNA was then made from 1 microgram of RNA using iScript cDNA Synthesis Kit (BioRad Life Science). Primers are listed in table 2.2; run conditions were 95ᵒC for 10 s, 58ᵒC
for 15 s, 70ᵒC for 15 s. Samples were run in duplicate on a Bio-rad CFX Real Time
thermocycler. Relative expression was determined using the ΔΔCt method.
ChIP Assay
Macrophages were stimulated with IL4 or LPS+IFNγ for 24 h with or without
emodin. They were then fixed in 1% formaldehyde. Excess formaldehyde was quenched
with glycine and the cells were collected in PBS by scraping. The cells were incubated in
lysis buffer (0.5% IGEPAL, 4 mM HEPES) for 15 min on ice. The nuclei were
centrifuged at 1000xg for 5 min and were resuspended in nuclear lysis buffer (1% SDS,
10 mM EDTA, and 50 mM Tris, pH 8.1). The DNA was sheared by sonication using a
Diagnode Bioruptor Pico for 15 cycles of 30 s on/30 s off. A small fraction of DNA was
taken from each sample and eluted from the protein by incubating the sample with
Proteinase K at 62ᵒC for 2 h in elution buffer. The DNA was purified using Zymo
research’s ChIP DNA Clean and Concentrator kit. The efficiency of shearing was
evaluated by running the samples on a 1% agarose gel and the amount of DNA in each
sample was quantified by detecting absorbance at 260 and 280 nm. Samples containing a
DNA smear between 1000-200 BP were used for the ChIP assay, a representative gel is
shown in figure 2.1. For the ChIP assays, 10 µg chromatin was diluted 1:10 (0.01% SDS,
1.1% Triton X- 100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl) and 2%
of the input was removed from each sample and saved for analysis. Anti-H3K27m3 or
anti-H3K27ac (Abcam) was added to each sample along with 20 µl of protein A+G
magnetic beads (Millipore) and the samples were incubated overnight at 4 ᵒC on a
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rocking platform. The beads were washed with low salt, high salt, LiCl, and TE wash
buffers sequentially for 5 min each and the DNA was eluted off the beads with Proteinase
K at 62 ᵒC for 2 h (elution buffer: 200 mM NaCl, 1% SDS and 50 mM Tris). The DNA
was purified using Zymo research’s ChIP DNA Clean and Concentrator kit; 50 µl of
water was used to elute the DNA off of the columns. The DNA was then analyzed by real
time PCR using primers listed in table 2.3.
Statistical analysis—
For microarray analysis, data was extracted from images with Feature Extractor
Software version 10.7.3.1 (Agilent); background correction using detrending algorithms
was performed. Subsequently, background-corrected data was uploaded into GeneSpring
GX version 11.5.1 for analysis. In this process, data was log2 transformed, quantile
normalized and baseline transformed using the median of all samples. Then, data was
filtered by flags in a way that 3 out of the 4 biological replicates have a “detected” flag in
at least one of the three treatment groups. Differentially expressed genes were determined
by analysis of the data using the Mann-Whitney unpaired statistics. A cutoff p-value of
0.05 and a fold change cutoff value of 2.0 were used to filter the data. Pathway analysis
was performed using Ingenuity Pathway Analysis software.
For all other experiments, data were presented as mean ± standard error of the
mean (SEM). Statistical significance was calculated by 2-tailed Student’s t test (twogroup comparison) using the GraphPad Prism statistical program (GraphPad Software
Inc., San Diego, CA). p≤0.05 was considered significant.
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2.3 RESULTS
Emodin affects the activation of different transcriptional programs depending on the
nature of the stimuli.
LPS/IFNγ and IL4 induce macrophages to adopt opposing pro-inflammatory or
anti-inflammatory phenotypes, respectively, through the activation of different, often
mutually exclusive, signaling cascades. Therefore, we tested the ability of emodin to
inhibit macrophage response to these signals and analyzed gene expression using a whole
genome microarray. Mouse peritoneal macrophages were stimulated with LPS/IFNγ or
IL4 with or without emodin. We found that LPS/IFNγ stimulation changed the expression
of over 4,400 genes and IL4 changed the expression of over 700 genes (≥2 fold, p-value
≤ 0.05) (GEO accession number GSE73311). Figure 2.2A shows the effect of emodin
treatment on the expression of genes that are significantly increased (upper panel) or
decreased (lower panel) by LPS/IFNγ. Emodin treatment attenuated the LPS/IFNγ
induced changes in about 31% of the LPS/IFNγ responsive genes. Similarly, emodin
inhibited IL4 induced changes in almost 60% of IL4 responsive genes (Fig. 2.2B). These
results indicate that emodin significantly inhibited the transcription programs induced by
both M1 and M2 stimuli.
LPS/IFNγ and IL4 induce macrophage activation through competing signaling
pathways (STAT1 vs STAT6, IRF4 vs IRF5), resulting in very little overlap between the
transcriptional programs that they induce. Of the over 4,400 genes changed by LPS/IFNγ
and the 719 genes changed by IL4, only 387 genes could be found in both datasets (Fig.
2.2C, upper). The expression of almost 6,500 genes was changed by emodin in at least
one of the conditions; among them only 1,575 were changed in both groups (Fig. 2.2C,
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lower). Therefore, emodin treatment predominately affected different transcriptional
programs under the two different conditions. These results were confirmed with a
principle component analysis (PCA) of the genes that were significantly changed in at
least one of the treatment groups (~10,000 genes) (Fig. 2.2D). The samples within each
group cluster near each other with LPS/IFNγ treated cells clustering much further from
naïve cells than IL4 treated cells, indicating that M1 activation involves much greater
transcriptional changes than M2, in agreement with previous studies (173). Similarly,
there is significant distance between the two emodin treatment groups, indicating that
emodin treatment differentially affected the expression of transcriptional programs under
the different conditions.
Emodin inhibits the induction of signaling pathways associated with macrophage
polarization and function.
Next, we investigated which cell signaling pathways might be targeted by emodin
by performing a canonical signaling pathway analysis using Ingenuity IPA. The genes
influenced by emodin treatment were enriched for genes associated with immune cell
signaling, inflammation, cell adhesion, and metabolism. Figure 2.3 shows a list of
pathways with the highest significance. Several pathways were targeted by emodin under
both conditions, including: communication between immune cells, granulocyte adhesion,
NFкB signaling, and Toll-like receptor signaling. However, most of the pathways
targeted by emodin were unique to the different conditions. The genes changed by
emodin under LPS/IFNγ stimulation were enriched for M1 associated pathways: antigen
presentation, IL1 signaling, and iNOS signaling; whereas, the genes changed by emodin
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under IL4 stimulation were enriched for M2 associated pathways: IL4, JAK/STAT,
TGFβ, and VEGF signaling.
The expression of genes in these pathways is shown in Figure 2.4. Emodin
significantly attenuated the LPS/IFNγ induced changes in a large number of genes
including canonical M1 associated genes: proinflammatory cytokines IL1β, TNFα, and
IL6 (13.64, 2.01, and 3.25 fold reduction, respectively); proteases MMP2/9 (11.86 and
28.87 fold reduction, respectively); and antigen presentation genes CD86 and H2-Oa/b
(7.74, 3.85, and 6.42 fold reduction, respectively) (Fig. 2.4A).

Similarly, emodin

inhibited the IL4 induced expression of canonical M2 genes Arg1, Mrc1, and Ch3l3
(7.69, 2.29, and 4.24 fold reduction, respectively); and transcription factors SOCS1 and
IRF4 (22.9 and 97.43 fold reduction, respectively) both of which are necessary for M2
activation (21,22,174) (Fig. 2.4B). Emodin also increased the expression of CDKN1A
(p21) which has been shown to inhibit macrophage proliferation and activation
(175,176).
Interestingly, we also found that emodin treatment had inverse effects on a subset
of 86 genes under the two different stimuli (Table 2.4). For examples, emodin increased
the expression of some proinflammatory genes including TNFα, CXCL2, and CXCL10
(2.7, 60.6, and 15.5 fold, respectively) under IL4 stimulation while significantly
decreasing them (-2.47, -10.31, and -2.01 fold, respectively) under LPS/IFNγ stimulation
(Fig. 6). Similarly, emodin increased the expression of M2 genes YM1 and Mrc1 under
LPS/IFNγ stimulation (2.04 and 8.72 fold, respectively), while reducing them in IL4stimulated cells (Fig. 2.4 and Table 2.4). These results show emodin’s ability to tune
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macrophage phenotype back towards the center between the extremes of the M1 or M2
activation states.
The expression of several important genes for macrophage activation was
confirmed by qPCR (Figs. 2.5A and B). Emodin inversely regulated M1 genes TNFα,
CXCL2 and CXCL10, and M2 gene Mrc1, in the two settings. Interestingly, emodin
inhibited the expression of transcription factors IRF5 and SOCS1, and chemoattractant
CCL2 under both IL4 and LPS/IFNγ stimulation. In agreement with the microarray
results, emodin inhibited the expression of many pro-inflammatory mediators including
IL1β, iNOS, and IL6 as well as proteases MMP2 and 9 under LPS/IFNγ stimulation, and
inhibited M2 genes Arg1 and Chi3l3 under IL4 stimulation. Emodin also inhibited the
expression of receptors TLR4 and CSFr1 under LPS/IFNγ or IL4 stimulation,
respectively, which could further inhibit macrophages from detecting activation signals in
the environment. IRF4, a major regulator of M2 macrophage activation, was the most
down regulated gene by emodin under IL4 stimulation in the microarray dataset. We
examined the production of IRF4 protein and found that emodin dose dependently
inhibited IRF4 production (Fig. 2.5C).
Emodin inhibits functions of activated macrophages.
Next we investigated the effects of emodin on the functions of macrophages,
which were predicted to be inhibited by emodin in one or both of the groups based on
pathway analysis of the microarray results. We examined the phagocytic ability of
activated macrophages. Macrophages were pretreated with LPS/IFNγ or IL4 with or
without emodin for 24 h; then the cells were incubated with Fitc labeled E. coli
bioparticles. In agreement with previous studies (150,177), emodin treatment alone was
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able to increase phagocytic activity of naïve cells at the 6 h time point; however, emodin
decreased both LPS/IFNγ and IL4 induced phagocytosis. Both IL4 and LPS/IFNγ
stimulated macrophages showed time dependent increases in bioparticle uptake (6-8 fold
increase at 6 h). However, emodin significantly inhibited particle uptake under both
conditions (by almost 2 fold) (Fig. 2.6A). Next, macrophages were stimulated with
LPS/IFNγ or IL4 with or without emodin then their migration potential was detected.
Macrophages were seeded into the top chamber of transwell inserts and media containing
MCP1 (20 ng/ml) was placed in the bottom. Emodin significantly reduced macrophage
migration under both conditions (Fig. 2.6B). M1 macrophage expression of iNOS leads
to the synthesis of large amounts of NO which is cytotoxic and is effectively used to kill
invading organisms. However, excessive NO production can also damage surrounding
cell populations. Since the expression of iNOS was significantly decreased by emodin,
we then verified emodin’s ability to inhibit M1 activation by detecting NO production.
Macrophage production of NO was measured in the culture media following stimulation
with LPS/IFNγ for 24 h. The result showed that emodin dose dependently inhibited NO
production decreasing NO levels by 57% at 25 µM and 96% at 50 µM (Fig. 2.6C).
Emodin modulates IL4 and LPS/IFNγ induced activation of cell signaling pathways.
We next attempted to identify the cell signaling pathways targeted by emodin
under the different conditions. Ingenuity’s Upstream regulator analysis of the microarray
date set was unable to identify a single high probability molecular target or casual
network for emodin under the different conditions, but instead provided many different
possible targets. Macrophage polarization is controlled by multiple different signaling
pathways which coordinate to fine tune the functional phenotype. LPS promotes M1
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macrophage activation by signaling through NFκB and MAPK pathways while IFNγ
mainly signals through the STAT1 pathway. IL4 stimulation leads to STAT6 pathway
activation along with several secondary transcription factors including IRF4. Nuclear and
cytoplasmic fractions of macrophages treated with LPS/IFNγ or IL4 and emodin were
analyzed using western blotting to detect nuclear translocation of transcription factors. In
agreement with previously published results (125,133,148), emodin was able to
drastically inhibit NFκB p65 nuclear translocation in response to LPS/IFNγ stimulation
(Fig. 2.7A) and STAT6 nuclear translocation in response to IL4 stimulation (Fig. 2.7B).
Emodin also inhibited nuclear accumulation of IRF4 (Fig. 2.7B), in agreement with our
gene expression data. Further, we found that emodin inhibited STAT1 and IRF5 nuclear
translocation (Fig. 2.7A). These results indicate that emodin is able to inhibit the key
signaling pathways necessary for macrophage polarization.
Emodin inhibits IL4 and LPS/IFNγ induced changes in the epigenetic landscape in
macrophages.
The microarray revealed that emodin changed the expression of several histone
modifying enzymes including those that regulate H3K27 methylation and acetylation
under both IL4 and LPS/IFNγ stimulation (Table 2.5). H3K27me3 attenuates M2
polarization by inhibiting the expression of IRF4; therefore, its removal by demethylase
JMJD3 promotes M2 activation (22,23). H3K27ac has been shown to prime both M1 and
M2 genes for expression upon subsequent stimulation (23,178). Therefore, we next
investigated emodin’s effects on these histone modifications in macrophages. We
investigated the global expression of these histone modifications using western blotting
and found that emodin had no effect on the global expression of either H3K27m3 or
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H3K27ac (Fig. 2.8A). We then examined gene specific changes in histone modifications
using ChIP assays. We found that emodin attenuated the LPS/IFNγ-induced decrease of
H3K27m3 in the promoter of iNOS, TNFα and IL6 genes, and reversed the IL4-induced
decrease of H3K27m3 in the promoter of IRF4, Arg1 and YM1 genes. Emodin also
suppressed LPS/IFNγ-induced increase of H3K27ac in the promoters of iNOS, TNFα and
IL6 genes, and IL4-induced increase of H3K27ac in the promoter of IRF4 and YM1
genes (Figs. 2.8B and C). These data for the first time show that emodin epigenetically
regulates macrophage activation. Further, unlike emodin’s effects on signaling pathways,
emodin’s effects on histone modification are not stimuli dependent, but gene specific.
Recent studies have revealed that macrophages are able to retain a memory of the
environmental signals to which they have been exposed, allowing them to alter their
response upon subsequent stimulation. Therefore, we then investigated how emodin’s
effects on histone modifications affect macrophage memory. Macrophages were
stimulated with IFNγ or IL4 for 24 h with or without emodin. Then they were cultured in
fresh media for 2-5 d before being stimulated again with LPS or IL4, respectively, for 6 h
without emodin. There was no difference in the expression of iNOS after 2 d post
stimulation with IFNγ, while the expression of Arg1 was still slightly elevated 2 d post
IL4 treatment compared to the emodin treatment group (Figure 2.9D and E). However,
re-stimulation with LPS or IL4 resulted in significantly increased expression of iNOS or
Arg1, respectively, compared to cells stimulated for the first time, indicating that prior
treatment with IFNγ or IL4 boosted the responses to the subsequent exposures. However,
if the cells were concomitantly treated with emodin during the first IFNγ or IL4
treatment, their responses to the second treatment were significantly diminished;

33

particularly in the case of IL4 treatment, their response to a second IL4 treatment was
even lower than their first exposure (Figs. 2.9B and C). After 5 days of wash-out period,
there was no significant difference in the nuclear STAT1 or STAT6 in IFNγ or IL4
pretreated cells, respectively, regardless if the cells were also treated with emodin (Figs.
2.9F and G). The lack of differences in the STAT1 and STAT6 signaling pathway prior
to re-stimulation indicates that emodin may regulate macrophage memory through
epigenetic modification of the key genes in macrophage activation.
2.4 DISCUSSION
Taken together, these results reveal the ability of emodin to inhibit both M1 and
M2 polarization of macrophages through transcriptional and epigenetic regulation. LPS
and Th1 cytokine IFNγ stimulate macrophages to adopt an M1 pro-inflammatory
phenotype, while Th2 cytokine IL4 induces macrophages to an M2 anti-inflammatory
phenotype. Gene expression analysis of emodin treated macrophages revealed that
emodin attenuated the transcriptional changes in 60% of genes altered by IL4 and 31% of
the genes altered by LPS/IFNγ. Emodin mostly targeted different transcriptional
networks in the two different stimulation settings, indicating emodin’s ability to
differentially affect a broad-spectrum of signaling pathways depending on the
microenvironment. Further analysis revealed that emodin inversely regulated a subset of
genes including Mrc1, YM1, TNFα, CXCL2, and CXCL10 in LPS/IFNγ or IL4 treated
macrophages. Emodin inhibited macrophage migration and phagocytosis regardless of
the stimuli by suppressing common pathways in the two different settings. Emodin was
able to inhibit numerous signaling pathways including NFκB, STAT1, and IRF5
following LPS/IFNγ stimulation, and STAT6 signaling triggered by IL4 stimulation.
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Emodin also inhibited IRF4 production by increasing H3K27m3 on its promoter region.
Finally our data showed that emodin was able to inhibit the ability of macrophage
training/memory. When administered along with the initial stimuli (IL4 or IFNγ), emodin
diminished the response to a second stimuli (IL4 or LPS, respectively). Taken together,
our data show that emodin has great potential as a treatment for pathologies driven by an
imbalance in macrophage activation and polarization.
It has been implied in literature that emodin may have different effects on
macrophages depending on the environment of the cells being studied. The majority of
studies performed on emodin have focused on its ability to shift the Th1 inflammatory
response to Th2 (125). Emodin inhibits inflammatory cytokine production in a variety of
settings, often through blocking NFκB and MAP kinase signaling. Emodin has also been
shown to promote expression of M2 associated molecules TGFβ and PPARγ (125,142).
On the other hand, there have been a few studies which have implied that emodin may
also be capable of suppressing Th2 responses. Emodin significantly inhibited the
secretion of Th2 cytokines IL4, IL5, and IL13 in the lungs of mice challenged with OVA
(145,179). Further, our lab has found that emodin is able to inhibit breast cancer
metastasis to the lungs in mice by reducing macrophage infiltration and M2 polarization
through inhibiting STAT6 and C/EBPβ signaling (148). But the interesting dual effects of
emodin on macrophages have not been comprehensively studied.
Based on our data, we suggest that emodin is a bi-directional regulator of
macrophage activation, and that it is able to target multiple signaling pathways in
macrophages to return their phenotype to the homeostatic center between the extremes of
M1 or M2 activation in various environmental settings. Our results show that emodin is
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able to effectively inhibit macrophage response to both LPS/IFNγ and IL4. In agreement
with previous studies, emodin was able to inhibit proinflammatory cytokine/chemokines
expression through blocking NFκB signaling in response; however, we also found that
emodin was able to inhibit STAT1 signaling as well. Under IL4 stimulation, emodin
inhibited M2 activation markers through blocking STAT6 signaling. Emodin’s ability to
inhibit STAT signaling in macrophages is in agreement with previous studies which have
shown that emodin can interfere with the JAK-STAT signaling pathway in human cancer
cells. Muto and colleagues found that emodin could block STAT3 phosphorylation and
activation in response to IL6 by inhibiting the activation of JAK2 in multiple myeloma
cells (158). Similarly, Zheng et al. showed that emodin could inhibit JAK1/2 activation
and subsequently block phosphorylation of STAT1, 3, and 5 in response to Oncostatin M
and IFNγ in several human cancer cell lines (180). In hepatocarcinoma cells emodin
inhibited JAK1/2 activation by inducing the expression of SHP-1 phosphatase (181).
For the first time our results show that emodin is also able to regulate the IRF
signaling pathways. IRF4 and 5 have been shown to be inversely regulated, pushing
macrophages toward an M2 or M1 phenotype, respectively (14,27). IRF5 is activated by
TLR4 ligation and promotes the transcription of pro-inflammatory genes (e.g. IL12b)
while also suppressing the expression of anti-inflammatory genes (e.g. IL10) (16). IRF4
competitively binds to MyD88 and is a negative regulator of IRF5 signaling. IRF4 helps
to fine tune the M2 phenotype in response to parasite infections, and is regulated through
the removal of H3K27m3 by the histone demethylase JMJD3 (22,27,182). Our results
show that emodin is able to inhibit both IRF4 (which was the most downregulated gene
under IL4 stimulation) and IRF5 signaling. Also, for the first time, we showed that
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emodin can inversely regulate the expression of several key M1 and M2 markers. Emodin
inhibited the expression of pro-inflammatory cytokines/chemokines TNFα, CXCL2,
CXCL10 in macrophages under LPS/IFNγ stimulation while increasing the expression of
M2 markers YM1 and Mrc1 which were suppressed by LPS/IFNγ. Similarly, emodin
inhibited the expression of M2 markers Mrc1 and YM1 in macrophages exposed to IL4
but increased the expression of pro-inflammatory TNFα, CXCL2, and CXCL10 which
were downregulated by IL4. These findings are in agreement with previous studies in our
lab showing that pro-inflammatory cytokines are decreased by emodin treatment in the
serum of mice with a Th1/M1 driven pathology (High fat diet fed mice treated with LPS)
(133), but the levels of proinflammatory cytokines TNFα, IL12, and IL17 are all
increased by emodin treatment in the serum of mice with a Th2 driven pathology (148).
Taken together, these data indicate that emodin is able to target multiple antagonistic
signaling pathways (STAT1 vs. STAT6, IRF5 vs. IRF4) to inhibit macrophage activation
and return them to a homoeostatic state which gives emodin great potential as a therapy
to target diseases in which imbalanced macrophage activation plays a major role.
Macrophages can retain a memory of signals that they are exposed to which helps
to shape their response to future stimulation (27, 28, 90). This memory is predominately
regulated by epigenetic mechanisms, especially histone modifications. Cytokines such as
IFNγ can prime genes for increased expression by the recruitment of transcription
promoting histone markers (such as H3K4m3, H3K9m3 and H3K27ac) to the promoter
or enhancer regions (32). Similarly pro-longed exposure to foreign molecular patterns
could lead to increased or decreased immune response (for examples, β-glucan or LPS,
respectively) (178). The microarray revealed that emodin significantly changed the
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expression of several histone modifying enzymes, particularly those responsible for
regulating H3K27 tri-methylation and acetylation. However, emodin had no effects on
genome wide levels of H3K27ac and H3K27m3; instead, it significantly increased
H3K27m3 levels while decreasing H3K27ac levels on the promoters of many M1 genes
and M2 associated genes. Our data revealed that emodin was able to modulate
macrophage memory. Pre-stimulation of macrophages with IFNγ or IL4 resulted in
exaggerated M1 or M2 responses to subsequent stimulation with LPS or IL4,
respectively, up to 5 days later. Emodin treatment during the pre-stimulation stage
significantly diminished the exaggerated responses, even though prior to second
stimulation expression of iNOS or Arg1 were back to similar levels regardless of emodin
pretreatment. Similarly, there was no difference in STAT1 or STAT6 activation prior to
second stimulation. Therefore, these data suggest that at least part of emodin’s effects on
macrophage activation and memory could be attributed to gene specific epigenetic
modifications.
In summary, emodin effectively inhibited macrophage activation in response to
both M1 and M2 stimuli by suppressing the activation of multiple signaling pathways
including NFκB, IRF5, MAPK, STAT1 or STAT6 and IRF4 depending on the
environmental settings. Emodin thus regulated a subset of genes depending on whether
the cell was exposed to M1 or M2 stimuli, pushing the phenotype of the cell back toward
the center of the two poles. This phenomenon opens the possibility that emodin may exert
very different homeostasis maintaining effects on macrophages in different locations and
thus target two very different pathologies within a same individual. Finally we showed
for the first time that emodin is able to modulate macrophage activation and memory
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through increasing H3K27m3 and decreasing H3K27ac on promoters of M1 or M2
associated genes. Taken together, our data show the potential of emodin to be used as a
therapy for the numerous pathologies which are driven by an imbalance of macrophage
phenotypes.
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Table 2.1 Antibodies used for western blots and ChIP procedures.
Antibodies
p65
STAT1
STAT6
IRF4
IRF5
Actin
TBP
H3K27m3
H3K27m3
H3K27ac
H3
Anti-rabbit
HRP
Anti-Mouse
HRP
Anti-goat
HRP

Procedure
Western
Western
Western
Western
Western
Western
Western
ChIP
Western
Western/Chip
Western
Western

Product #
8242
sc-346
9362
sc-6059
4950
A2066
ab51841
ab6002
07-449
AB4729
05-928
sc-2004

Company
Cell Signaling
Santa Cruz
Cell Signaling
Santa Cruz
Cell Signaling
Sigma
Abcam
Abcam
Millipore
Abcam
Millipore
Santa Cruz

Western

sc-2005

Santa Cruz

Western

sc-2024

Santa Cruz
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Table 2.2 Primers for RT-qPCR
Primers

Forward

Reverse

18s

CGCGGTTCTATTTTGTTGGT

AGTCGGCATCGTTTATGGTC

TNF

CGT CAG CCG ATT TGC TAT CT

CGGACTCCGCAAAGTCTAAG

CXCL2

CGCTGTCAATGCCTGAAG

GGCGTCACACTCAAGCTCT

CXCL10

TGAATCCGGAATCTAAGACCATCAA

AGGACTAGCCATCCACTGGGTAAAG

MRC1

TGGATGGATGGGAGCAAAGT

AATGCCAACCTTCCTTGCAG

IRF5

CAGGTGAACAGCTGCCAGTA

CTCATCCACCCCTTCAGTGT

SOCS1

TTAACCCGGTACTCCGTGAC

GAGGTCTCCAGCCAGAAGTG

CCL2

CAGGTCCCTGTCATGCTTCT

TCTGGACCCATTCCTTCTTG

IL1b

GCCCATCCTCTGTGACTCAT

AGGCCACAGGTATTTTGTCG

INOS

CACCTTGGAGTTCACCCAGT

ACCACTCGTACTTGGGATGC

IL6

AGTTGCCTTCTTGGGACTGA

TCCACGATTTCCCAGAGAAC

TLR4

GCTTTCACCTCTGCCTTCAC

GAAACTGCCATGTTTGAGCA

MMP2

ACACTGGGACCTGTCACTCC

GCGAAGAACACAGCCTTCTC

MMP9

CATTCGCGTGGATAAGGAGT

ACCTGGTTCACCTCATGGTC

Arg1

TTTTTCCAGCAGACCAGCTT

GGAACCCAGAGAGAGCATGA

Chi3l3

TGGAATTGGTGCCCCTACAA

CCACGGCACCTCCTAAATTG

IRF4

GCAGCTCACTTTGGATGACA

CCAAACGTCACAGGACATTG

CSFr1

TTGGACTGGCTAGGGACATC

GGTTCAGACCAAGCGAGAAG

CDKNn1a CAAAGTGTGCCGTTGTCTCT

AGGAAGTACTGGGCCTCTTG

Table 2.3 Primers for ChIP-PCR.
Forward

Reverse

Region
P

IP

INOS-1 TCCCTAGTGAGTCCCAGTTTTGA

CTGGTCGCCCGTCCAAGG

H3K27m3

INOS-2 GCGCTCTAGTGAAGCAAAGG

TCTTAGTGGCCCAGGACAAG CpG

H3K27ac

TNF

AGGAGAAGGCTTGTGAGGTC

GAGTTGGGAAGTGTGCATGG P

H3K27m3

IL6

AGGAGTGTGAGGCAGAGAGC

GTCTCCTCTCCGGACTTGTG

Intron H3K27m3

IRF4

CACGTGATGGTCTCTGGTTG

TCATCCCACTTTTCCCTCAC

P

ARG1-1 TGAACAGGCTGTATTAGCCAACA AGCACCCTCAACCCAAAGTG P

H3K27m3,
H3K27ac
H3K27m3

ARG1-2 AGTTCCTCTGATGGGGAGGT

TCATGCTCTCTCTGGGTTCC

H3K27ac

YM1

ACACCCCTGAGCTTTGGTAA P

ACTTGCAACTACTCTGCACT

P=promoter
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P

H3K27m3,
H3K27ac

Table 2.4 Genes that were inversely regulated by emodin under the two different
treatments.
Gene

Rab3il1

Em+LPS Em+IL4 Gene
Em+LPS Em+IL4
vs
vs IL4
vs
vs IL4
LPS/IFN
LPS/IFN
2.66
-16.18 D230044B12Rik
2.39
-2.3

Mrgprg

2.18

Gprc5c

3.74

Ikzf2

8.72

-2.29

-8.77 Rassf2

2.62

-2.29

3.42

-6.36 Acp5

2.02

-2.22

Kctd12b

3.62

-5.06 Inpp5j

5.52

-2.21

Ear1

2.04

-4.71 AA914427

3.21

-2.2

Jakmip1

9.59

-4.67 A430110L20Rik

2.47

-2.19

2.02

-2.19

Trim45

4

-16.05 Mrc1

-4.6

Metrnl

Snn

2.13

-4.52 Gm9484

3.19

-2.13

Chi3l3
Cmbl

2.04
5.87

-4.24 Gdf3
-4.21 Selp

3.34
3.09

-2.12
-2.08

Ubtf

2.47

-4.2

3.05

-2.04

Xpo7

2.41

-4

Cdk14

-2.71

2.03

Ear2

2.03

-4

3930401B19Rik

-2.72

2.04

Gpr77

3.05

-3.22

2.06

Mnt

2.31

-2.21

2.06

Gm4610

Ier5l

-3.71 Tgfbi
-3.7

Cpd

8.8

-3.53 Fzd1

-2.45

2.08

Igf1

2.12

-3.47 Klra2

-14.35

2.1

Armcx6

2.81

-3.43 Prkar2b

-4.32

2.12

S100a4

3.02

-3.36 Apol9a

-4.48

2.16

Islr2

3.58

-3.34 Chpt1

-4.06

2.2

Sult1a1

2.95

-3.15 Ass1

-6.11

2.22

9230110K08Rik

3.15

-2.88 Slc7a3

-3.03

2.23

Senp8
Zfp473

2.13
3.06

-2.88 Gm20186
-2.82 Procr

-2.65
-2.07

2.26
2.38

Itga4

4.86

-2.82 Ppap2b

-2.13

2.55

Cables1

3.87

-2.76 Ptgs2

-3.99

2.56

Klf11

2.47

-2.74 Tnf

-2.01

2.69

A930006K02Rik

2.18

-2.72 Clec4n

-2.63

2.94

BC031361

2.05

-2.68 Smtnl2

-4.06

2.96

6430531B16Rik

2.25

-2.65 Thbs1

-6.51

3.22

Taf6l

2.04

-2.62 Jag1

-11.28

3.54

Nudt16l1

2.01

-2.59 Dusp14

-3.14

3.62
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Tbc1d16

3.26

-2.57 Hmga2

-2.02

3.79

Scgb2b27

2.23

-2.56 Pla2g5

-4.28

4.26

BC025920

2.91

-2.51 Flrt3

-4.09

4.37

Ccl9

5.28

-2.48 Cck

-25.26

4.53

Bcl9

2.64

-2.43 Serpine1

-23.78

6.13

1700097N02Rik

2.01

-2.42 Clec9a

-4.62

7.13

Gzmm

3.64

-37.91

7.37

Ear11
Hfe

3.2
3.09

-2.39 Tnfaip6
-2.36 Cxcl10

-16.37
-10.31

9.27
15.05

AW555355

2.31

-2.34 Cxcl2

-2.47

60.63

-2.4

Cxcl3

Table 2.5 Histone modifying enzymes significantly changed by emodin compared to
LPS/IFNγ (left) or IL4 (right) treatment.
Histone modifying enzymes changed by emodin
LPS LPS+Em
IL4
EZH1
N.C. 6.63
EZH1
N.C.
EZH2
N.C. 2.73
EZH2
N.C.
Hdac1
N.C. -2.3
Hdac1
N.C.
Hdac8
N.C. -4.08
Hdac8
N.C.
KAT2B
2.33 -4.69
Hdac9
N.C.
KAT6B
-2.41 3.65
KAT2B
N.C.
KDM3B
N.C. 2.12
KAT6B
N.C.
KDM4A
N.C. 9.21
KDM2A
N.C.
NCOA3
N.C. 2.58
KDM4A
N.C.
NSD1
-2.06 2.46
KDM4B
N.C.
PHF8
-2.35 3.62
KDM5B
N.C.
PRDM2
2.18 3.78
KDM6B
-2.2
SETD1B
N.C. 2.09
Mll1
N.C.
SETD7
N.C. 2.06
Mll2
N.C.
Sirt5
-2.06 -4.41
NCOA2
N.C.
Sirt7
N.C. 2.06
PHF8
N.C.
SMYD2
N.C. -3.02
PRDM2
N.C.
SUV420H1 N.C. 3.06
Sirt7
N.C.
Mll1
N.C. 3.09
SMYD3
N.C.
SUV420H1 N.C.
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IL4+Em
-6.26
-2.04
2.32
2.33
4.39
3.81
-2.7
2.04
-7.58
2.11
-2.13
1.91
-2.2
-2.64
2.6
-5.6
-2.26
-2.3
-2.79
-2.46

Figures

1000
800
600

400
200

Figure 2.1 DNA fragmentation for ChIP assays. Samples were run on a 1% agarose
gel along with a 100 base pair ladder and stained with ethidium bromide.
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B

Normalized Intensity
Values

A

Con

C

LPS/IFNγ

LPS/IFNγ+Em

D

Con

IL4

IL4+Em

Principal component analysis

Figure 2.2 Emodin inhibits LPS/IFNγ and IL4 induced transcriptional changes in
macrophages. Mouse peritoneal macrophages were stimulated with LPS (100 ng/ml) and
IFNγ (20 ng/ml) for 24 h (A) or IL4 (10 ng/ml) for 6 h (B) with or without emodin (50
μM). Gene expression was then detected using a whole genome microarray. A and B,
Genes significantly increased (top panel) or decreased (bottom panel) by LPS/IFNγ or
IL4, respectively. Y-axis corresponds to normalized intensity values for gene expression
and the x-axis to treatments. Each line represents one gene and the red and green colors
mark high and low expression of genes, respectively, in the LPS/IFNγ or IL4 treatment
groups. C, Venn diagrams showing genes significantly changed by LPS/IFNγ or IL4 and
by emodin under LPS/IFNγ or IL4 stimulation. D, Principle component analysis of genes
significantly changed in one of the treatment groups.
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Figure 2.3 Emodin inhibits the induction of signaling pathways associated with
macrophage polarization and function. Most significantly affected pathways relevant
for macrophage activation determined by Ingenuity IPA canonical pathway analyses.
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A

Gene
Symbol
H2-Ob
IL1RL1
MMP2
CD86
SELL
IFIT1
MYH3
MMP9
IRF5
CCL2
RASGRP1
FPR2
IL1B
CXCL10
CCL5
TNF
IL12A
SOCS1
IRF7
H2-Oa
CXCL2
CXCL3
IL12B
IL6
NOS2
PTGS2
Mrc1
TLR4

Con

LPS/IFN

LPS/IFN+Em
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LPS/IFN vs
Con
6.30
9.66
7.57
17.11
15.77
25.61
3.48
7.65
1.30
96.07
75.14
401.98
358.98
770.25
238.95
79.29
77.45
110.62
82.09
32.62
33.32
32.80
838.87
1814.11
3043.88
3745.38
-8.48
-1.72

Em+LPS vs
LPS/IFN
-6.42
-10.78
-11.86
-7.74
-10.56
-11.94
-7.76
-28.87
-2.11
-12.06
-9.52
-33.81
-13.64
-10.31
-5.41
-2.01
-4.93
-5.34
-4.20
-3.85
-2.47
-2.47
2.47
-3.25
-3.77
-3.99
8.72
-4.71

Gene
Symbol

B

CDKN1A
CXCL2
CCL28
CXCL10
CXCR1
TNF
PLA2G5
MMP13
PTGS2
Arg1
CISH
SOCS1
FLT1
RBP4
CCL11
IL19
IRF4
ITGB8
Mrc1
FCGR2B
SOCS2
CDH1
IL6
CCL7
CCL12
Ccl2
IL1R1
Chi3l3
IRF5

Con

IL4

IL4 vs
Con

Em+IL4
vs IL4

1.08
-2.24
2.45
-4.60
-3.45

29.78
60.63
2.27
15.05
12.40

-2.16
4.15
8.35
4.85
136.43
474.12
29.55
22.64
34.94
14.11
20.98
27.25
4.23
4.28
5.32
8.70
10.19
7.70
20.39
20.08

2.69
4.26
3.68
2.56
-7.69
-7.11
-22.90
-27.09
-15.56
-11.31
-20.01
-97.43
-4.32
-2.29
-2.15
-5.47
-5.72
-5.30
-4.16
2.30

3.51
3.25
6.97
-1.06

-4.26
-2.15
-4.24
-2.58

IL4+Em

Figure 2.4 Effects of emodin on the expression of genes that regulate macrophage
activation. A and B, heat maps showing expression of genes associated with the most
significantly affected macrophage canonical signaling pathways. Tables on the right
show the fold changes of genes caused by LPS/IFNγ or IL4 treatment compared to
control and emodin treatment compared to LPS/IFN or IL4 for select macrophage
activation genes.
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Figure 2.5 Emodin inhibits expression of M1 and M2 genes. A and B, qPCR was
performed to verify the microarray results for select M1 and M2 genes. Bars represent
the mean ± S.E. For each treatment, n = 4. C, Macrophages were stimulated with IL4
with or without emodin (0-50 μM) for 6 h. The cells were lysed and IRF4 protein levels
were detected by western blotting. Results are shown as the means ± S.E. for two
independent experiments (n=4) * p<0.05, **p<0.01, ***p<0.001.
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Figure 2.6 Emodin modulates functions of activated macrophages. Mouse peritoneal
macrophages were stimulated with LPS (100 ng/ml) and IFNγ (20 ng/ml) or IL4 (10
ng/ml) with or without emodin (50 μM) for 24 h. A, Macrophages were washed and the
cells were incubated with FITC labeled E. coli bioparticles for 4-6 h. Fluorescence was
detected with a microplate reader as an indicator of phagocytosis. Results are shown as
the means ± SE (n=4). B, Macrophages were seeded into the top chamber of a transwell
insert in DMEM, and DMEM with MCP1 (20 ng/ml) was placed in the bottom of the
well. After 4 h, cells were fixed, stained with Dapi, and imaged with 5 fields of view at
20x magnification per membrane. Results are shown as the means ± SE for two
independent experiments (n=3). C, Macrophages were incubated with LPS/IFNγ with
emodin at various concentrations. After 24 h the media was collected and NO content
was detected. Results are shown as the means ± SE (n=4).* p<0.05, **p<0.01,
***p<0.001.
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Figure 2.7 Emodin inhibits LPS/IFNγ and IL4 induced activation of signaling
pathways. Macrophages were stimulated with (A) LPS (100 ng/ml) and IFNγ (20 ng/ml)
or (B) IL4 (10 ng/ml) with or without emodin (50 μM) for 24 h. Cells were lysed and
cytoplasmic and nuclear fractions were collected. Transcription factors were then
detected in the nuclear fraction using western blotting. Bottom panels, quantification of
blots normalized to loading controls TBP or Ponceau S. Results are shown as the means ±
SE for two independent experiments (n=4). * p<0.05, **p<0.01, ***p<0.001.
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Figure 2.8 Emodin inhibits LPS/IFNγ and IL4 induced histone modifications in
macrophages. Macrophages were stimulated with LPS (100 ng/ml) and IFNγ (20 ng/ml)
or IL4 (10 ng/ml) with or without emodin (50 μM) for 24 h. A, Global histone
modification levels were detected using western blotting. Experiment was performed in
triplicate (n=3). B and C, ChIP-PCR was used to detect gene specific changes in histone
modifications. Results are shown as the means ± SE (n=3). *p≤0.05; **p≤0.01.
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Figure 2.9 Emodin inhibits macrophage memory. A, Diagram of macrophage
treatments for macrophage training experiments. B and C, Macrophages were incubated
with IFNγ (20 ng/ml) or IL4 (10 ng/ml) with or without emodin (50 μM) for 24 h. Then
the cells were washed and incubated for 2 or 5d. The macrophages were then stimulated
with either IL4 or LPS for 6 h and the gene expression was analyzed with qPCR. Results
are shown as the means ± SE for two independent experiments (n=3). D and E, Gene
expression in macrophages after the 2 d rest period. F and G, Macrophages were lysed
after the 5 d rest period and cytoplasmic and nuclear protein fractions were collected and
analyzed via western blotting. *p≤0.05; **p≤0.01

53

CHAPTER 3
EMODIN INHIBITS BREAST CANCER GROWTH BY
MODULATING THE TUMOR MICROENVIRONMENT
3.1 BACKGROUND
Since emodin’s ability to regulate macrophage polarization was established, we
then sought to investigate its therapeutic potential in a disease model dependent on
macrophages for progression. In spite of the many advances that have been made, breast
cancer is still the second leading cause of cancer deaths among women (183). Tumor
growth and metastasis depend on the support from stromal cells including macrophages,
fibroblasts,

and

myeloid

derived

suppressor

cells

(MDSCs)

in

the

tumor

microenvironment (TME) which promote angiogenesis, matrix remodeling, and
immunosuppression (56,184). Recently there has been interest in immunotherapies for
the treatment of breast cancer because of their low toxicity and extended duration of
action (185,186). However, the immunosuppressive microenvironment of tumors greatly
diminishes the effectiveness of these therapies (187,188). MDSCs, M2-like tumor
associated macrophages (TAMs), and regulatory T cells have all been shown to repress
an effective anti-tumor immune response through the production of anti-inflammatory
cytokines and growth factors such as IL10 and TGFβ. Therapies targeting the
immunosuppressive microenvironment have shown great potential on their own or in
combination

with

other

therapies

in

54

experimental

models

(92,189,190).

Therefore, we investigated emodin’s ability to inhibit breast cancer growth
through modulating the tumor microenvironment (TME). Emodin treatment significantly
reduced the size of EO771 and 4T1 breast tumors. Emodin reduced macrophage
infiltration into the tumors and their M2-like activation through inhibiting STAT6,
C/EBPβ, and IRF4 signaling pathways and through inhibiting changes in histone
modifications. In vitro studies showed that emodin was also able to inhibit tumor cell
secretion of macrophage chemoattractants and growth factors. Further, we found that
emodin treatment increased T cell activation indicating that the emodin was able to
inhibit the immunosuppressive environment of the tumors.
3.2 DETAILED METHODS
Tumor cell culture and conditioned medium collection
The 4T1 cells, obtained from the American Type Culture Collection (ATCC), and
EO771 cells, developed from an ER+ spontaneous mammary adenocarcinoma (191,192),
were grown in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen,
Grand Island, NY) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin
(Sigma-Aldrich, St. Louis, MO), and 100 μg/mL streptomycin (Sigma-Aldrich) at 37 ᵒC
in a humidified CO2 incubator. For tumor conditioned medium collection, cells were
grown until they were 80-90% confluent. Then the media was replaced with serum free
(SF) DMEM and the cells were cultured for 48 h. The media was then collected and
passed through a 0.45 µm filter (Millipore Corp., Bedford, MA). The media was
concentrated 10:1 using centrifuge filters with a 3000 MW cutoff (Millipore) and stored
at -80ᵒC. Before use the media was diluted 1:2 with fresh SF DMEM so that the final
concentration of the TCM was 5x.
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Tumor models
C57BL/6 and BALB/c mice (8-12 week, female) were purchased from Jackson
Labs (Bar Harbor, Maine). They were housed at the University of South Carolina Animal
research facility and all procedures were approved by the Institutional Animal Care and
Use Committee. EO771 or 4T1 cells (2x105) were injected in 20 µL of PBS into the fat
pad of the 4th pair of mammary glands on C57BL/6 mice or BALB/C, respectively, on
day 0. Starting on day 1, emodin (40mg/kg) or vehicle (2% DMSO) was injected
intraperitoneally in 1 mL PBS once daily until the mice were sacrificed. The tumor size
was measured using calipers every 2-4 days once the tumors were large enough, and the
tumor volume was calculated using a formula: V (mm3) = L (major axis) x W2 (minor
axis)/2. Mice were sacrificed at various time points.
Isolation of tumor infiltrating cells
Macrophages or T cells were isolated from 4T1 tumors from mice sacrificed at 6
weeks post implantation or from EO771 tumors 5 weeks post implantation, using
EasySep™ Mouse PE Positive Selection Kit (Stem Cell Technologies, Vancouver, BC)
as previously described (193). Briefly, tumors were cut into small fragments (<3 mm)
and digested in 5 mls collagenase digestion buffer (RPMI 1640 medium containing 10%
FBS, Collagenase type I (4 mg/ml), Hyaluronidase (0.5 U/ml) and DNase I (20 μg/ml))
for 60 min at 37ᵒC with continuous shaking. The cell suspensions were then passed
through 70 µM cell strainers and centrifuged at 330xg for 5 min. Red blood cells were
then lysed by resuspending the cells in 6 mls RBC lysis buffer (Sigma, St. Louis, MO)
and incubating them for 5 min. The cells were then passed through a 70 µM strainer
again and resuspended in PBS containing 2% FBS. For cell isolation, 1x107-1x108 cells
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were incubated with 20 µL PE conjugated anti-F4/80 (Biolegend) for macrophages or 20
µL PE conjugated anti-CD3 for T cells and 50 µL microbeads. The T cells and 2-5x106
macrophages were lysed in Qiazol and used for RT-PCR analysis. For ChIP assays, 510x106 macrophages were fixed in 1% formaldehyde.
Flow cytometry
The tumor draining lymph nodes and tumors of the mice were collected and cell
populations were analyzed using flow cytometry as previously described (193). Briefly,
lymphocytes were isolated from lymph nodes by mechanical dissociation. Tumors were
cut into small fragments and incubated in collagenase digestion buffer to generate single
cell suspensions. Red blood cells were then lysed by resuspending the cells in 6 mls
RBC lysis buffer (Sigma, St. Louis, MO) and incubating them for 5 min. The cells were
then passed through a 70 µM strainer again and resuspended in staining buffer (PBS
containing 2% FBS). Cells were stained with anti-CD3 FITC, anti-CD4 APC or anti-CD8
APC, and anti-CD25 PE (Biolegend) in PBS containing 2% FBS for 30 min at 4 ᵒC.
Samples were washed twice with staining buffer and analyzed by flow cytometry using a
BD FACS flow cytometer and CXP software version 2.2 (BD Biosciences, San Jose,
CA). Data were collected for 20,000 live events per sample.
For Ki67 staining, 4T1 and EO771 tumor cells were seeded into 6 well plates and
cultured in SF DMEM overnight. They were then treated with various concentrations of
emodin (0-50 µM) for 24 h. The cells were resuspended with trypsin+EDTA and fixed
with 1% paraformaldehyde for 10 min. The cells were then permeablilized with 0.25%
Triton X-100 for 15 min. The cells were washed with PBS and stained with anti-Ki67 PE
(Abcam). The cells were washed and incubated with goat anti-rabbit alexa 488
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(Invitrogen, Eugene, OR). After washing, the samples were analyzed by flow cytometry
using a BD FACS flow cytometer and CXP software version 2.2. Data were collected for
10,000 live events per sample.
Immunohistochemistry
At sacrifice, tumors were embedded in OCT. They were then cut into 8 µm thick
frozen sections and placed on slides. For Immunohistochemistry (IHC) staining, the
sections were fixed with 4% paraformaldehyde for 10 minutes, then blocked with 0.01 M
glycine containing 0.1% Triton x-100. Next, the sections were blocked with 5% BSA.
They were then incubated in primary antibody overnight at 4 ᵒC: anti-F4/80 (1:50,
Biolegend), anti-pSTAT6 (1:50, Cell Signaling), anti-C/EBPβ (1:50, Santa Cruz). The
sections were washed with PBS and then incubated with secondary antibodies for 1 h at
room temperature. The sections were then stained with DAPI (5 µg/mL) and coverslipped
with DABCO. Slides were imaged using a Zeiss LSM 510 Confocal microscope (Zeiss,
Peabody, MA). For quantitative analysis, the number of positive cells was manually
counted in six random fields of view per section. CD31 staining was performed as
described previously (193). Briefly, tissue sections were fixed in acetone and washed
with PBS. They were then incubated with 3% hydrogen peroxide for 5 min and then
blocked with normal goat serum. Next they were incubated with anti-CD31 (1:100, BD)
at 4ᵒC overnight. The slides were then washed and incubated with biotin conjugated
secondary antibodies and AEC chromogen/HRP substrate kit (GeneTex, Irvine, CA)
according to the manufacturer’s instructions. The sections were counterstained with
hematoxylin and coversliped with DABCO. Slides were imaged on a Nikon ECLIPSE
E600 microscope (Nikon, Melville, NY) at 200x magnification (10 fields per section).

58

The integrated optical density (IOD) of CD31 was quantified using Image-Pro Plus
software.
Peritoneal macrophage isolation and treatment
Peritoneal macrophages were collected as described in Chapter 2. Mice were
injected with 3 mls of 4% Thioglycolate solution. After 3 days, macrophages were
collected by peritoneal lavage with PBS. The cells were resuspended in DMEM+10%
FBS and cultured for 2 h. The non-adherent cells were then washed away and the
remaining cells were cultured overnight in SF DMEM. The cells were then treated with
tumor conditioned medium (TCM) with or without emodin.
Quantitative real-time PCR (qPCR)
For qPCR, cells were lysed with Qiazol and RNA was extracted using Zymo
research Direct-zol RNA isolation kit. cDNA was then made from 1 µg of RNA using
iScript cDNA Synthesis Kit (Bio-Rad Life Science, Hercules, CA). Primers are listed in
Tables 2.1 and 3.1; run conditions were 95 ᵒC for 10 s, 58 ᵒC for 15 s, 70 ᵒC for 15 s.
Samples were run in duplicate on a Bio-rad CFX Real Time thermocycler. Relative
expression was determined using the ΔΔCt method.
Chromatin immunoprecipitation and global histone analysis
ChIP assays were performed as described in chapter 2 with few modifications.
Macrophages were fixed in 1% formaldehyde. Excess formaldehyde was quenched with
glycine and the cells were collected in PBS by scraping. The cells were lysed and the
nuclei were resuspended in nuclear lysis buffer. The DNA was sheared by sonication
using a Diagenode Bioruptor Pico (Diagenode, Denville, NJ) for 25 cycles of 30 s on/30 s
off. Then 8 µg chromatin was diluted 1:10 and 2% of the input was removed from each
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sample and saved for analysis. Anti-H3K27m3 (Abcam) was added to each sample along
with 20 µL of protein A+G magnetic beads (Millipore), and the samples were incubated
overnight at 4 ᵒC. The beads were washed with low salt, high salt, LiCl, and TE wash
buffers sequentially and the DNA was eluted off the beads with Proteinase K at 62 ᵒC for
2 h. The DNA was then analyzed by real time PCR using primers listed in Table 2.3.
In order to detect genome wide levels of histone H3 modifications, histones were
isolated from macrophages treated with TCM with or without emodin for 24 h using
EpiQuik total histone extraction kits (Epigentek, Farmingdale, NY) according to the
manufacturer’s directions. Briefly, macrophages were washed with PBS following
treatments and collected by scraping. Macrophages were resuspended in pre-lysis buffer
and incubated on ice for 10 min. The nuclei was then pelleted by centrifugation and
resuspended in approximately 40µl lysis buffer and incubated on ice for 30 min. The
lysate was centrifuged at 20,000xg for 5 min and the supernatant was collected. The
lysate was then neutralized with balance buffer and quantified using a BioRad DC protein
assay. Histones (100 ng) were then analyzed using an EpiQuik Histone H3 modification
kits (EpiGentek) according to the manufacturer’s instructions. The colormetric reaction
was detected on a Spectra Max M5 Microplate Reader (Molecular Devices, Sunnyvale,
CA).
T cell proliferation and activation assays
Peritoneal macrophages were isolated from C57BL/6 mice as described
previously. Cells were seeded into 10 cm plates and treated with EO771 conditioned
medium with or without emodin for 24 h. The cells were then washed with PBS and
resuspended by scraping. T cells were isolated from the spleens of C57BL/6 mice using
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EasySep T cell isolation kit (Stem Cell Technologies) according to the manufacturer’s
instructions. For the proliferation assay, T cells were labeled with CSFE (Biolegend). T
cells were suspended in 1 ml PBS and were added to 1 ml of 10 µM CSFE in PBS and
incubated in the dark at 37ᵒC for 10 min. The CSFE labeled cells were then wash with
RPMI1640 media containing 10% FBS. T cells were added then mixed with
macrophages and CD3/CD28 DYNA beads (ThermoFisher Scientific) in a 1:1:1 ratio and
added to 12 well plates in triplicate and cultured in RPMI1640 containing 10% FBS, 100
U/mL penicillin, and 100 μg/mL streptomycin. For the activation assay, the T cells were
collected after 24 h and stained with anti-CD3, anti-CD4, and anti-CD69 for 30 min at 4
ᵒC. The cells were then analyzed on a BD FACS flow cytometer. For the proliferation
assay, T cells were collected after 72 h and stained with anti-CD3 and anti-CD4. The
cells were analyzed for CSFE depletion on a Beckman Coulter FC500.
Tumor cell viability assay
Tumor cells (2x104 EO771 or 4T1 cells) were seeded into 96 well culture plates in
DMEM+10% FBS. The cells were incubated overnight at 37 ᵒC. The media was then
removed, and the cells were washed with PBS. DMEM containing varying concentrations
of emodin (0-100µM) was then added to the cells in quadruplicate. Control contained an
equal volume of DMSO. Plates of cells were then incubated for 24-48 hours. After the
stated time, the viability of the cells was determined using a Lactate Dehydrogenase
(LDH) Cytotoxicity Detection Kit (Clonetech Mountain View, CA) according the
manufacturer’s instructions. Briefly, the supernatant was removed from each well on the
plate and placed in a new well on the same plate. An equal volume of cell lysis buffer
(2% triton in DMEM) was then added to each well containing the cancer cells, and the
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cells were incubated at room temperature for 15 minutes. The reaction mixture was then
added to each well (cell lysate+supernatant) and incubated for 5 minutes before the stop
solution (1N HCl) was added. The absorbance was measured at 490 nm on a Spectra Max
M5 Microplate Reader (Molecular Devices, Sunnyvale, CA). The percent viability was
then calculated as the ratio of LDH in the cell lysate to the total amount of LDH in the
lysate plus the supernatant. The viability of each group was compared to the control.
Transwell migration assay
TCM was generated from tumor cells which had been pre-treated with various
concentrations of emodin. The EO771 or 4T1 cells were treated with 0-50 µM emodin for
24 h. Then the cells were washed multiple times with PBS, cultured for 48 h, and TCM
was collected as previously described. The TCM was placed in the bottom chamber of
transwell inserts and 2x105 peritoneal macrophages were seeded into the top chamber in
SF DMEM. The cells were incubated at 37 ᵒC with 5% CO2 for 4 h. The membranes were
then fixed with 4% paraformaldehyde for 10 min. The cells were removed from the top
chamber using cotton swabs, and the cells on the bottom chamber were stained with
DAPI (5 μg/mL). The inserts were then cut out, mounted onto slides, and imaged under a
Nikon Eclipse E-600 fluorescence microscope (Nikon Inc. Melville, NY) at 20 ×
magnification (5 fields/insert). DAPI stained cells were quantified using ImagePro Plus
software.
Macrophage adhesion assays
Tumor cell monolayers (80-90% confluent) and macrophages were treated with
emodin (0, 10, or 25 µM) overnight. Then the cells were washed multiple times with
PBS, and fresh SF DMEM was added. Macrophages were resuspended with scraping and
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5x105 cells were seeded onto the tumor cell monolayers. After 1 h the non-adherent cells
were washed away and the adherent cells were resuspended with Trypsin and mild
scraping. The total number of cells was counted, and the cells were stained with antiF4/80 FITC (Biolegend). The cells were analyzed on a Beckman Coulter FC500.
Statistical analysis
For all experiments, data were presented as mean ± standard error of the mean (SEM).
For two-group comparison, statistical significance was calculated by 2-tailed Student’s t
test. For multiple group comparison, one-way ANOVA was used followed by Tukey
multiple comparison test. All statistical analyses were performed using the GraphPad
Prism statistical program (GraphPad Software Inc., San Diego, CA). p≤0.05 was
considered significant.
3.3 RESULTS
Emodin inhibits breast tumor growth
In a previous study from our lab, when emodin treatment began after tumors were
well established (~200 mm3), it had no effect on the size of the primary tumor but
significantly reduced lung metastasis (148). We hypothesized that emodin might be most
effective in the inhibition of primary tumor growth when administered in the early stages
of tumor formation. Breast cancer EO771 and 4T1 cells were injected into the mammary
glands of C57Bl/6 or Balb/c mice, respectively, and emodin treatment (40 mg/kg IP once
daily) began 1 day after tumor cell injection. Emodin caused a significant inhibition of
primary tumor growth (Figure 3.1A) and reduced tumor size (Figure 3.1B) and tumor
weight (Figure 3.1C) at the endpoints in both EO771 and 4T1 models.
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Emodin inhibits macrophage infiltration and M2-like activation
Our previous study had shown that emodin could inhibit macrophage recruitment
and M2-like polarization in metastatic breast cancer in the lungs. Here we investigate
whether or not emodin also acts through macrophages in the inhibition of primary breast
cancer growth. First we examined macrophage infiltration and phenotype in EO771
tumor bearing mice at the experimental endpoint. Immunohistochemical analysis
revealed that emodin reduced the number of tumor infiltrating macrophages by 70%
(Figure 3.2A). We extracted F4/80+ cells from the tumors using magnetic beads and used
qPCR to examine the expression levels of M1 or M2 macrophage markers. qPCR showed
that TAMs in the emodin-treated mice had significantly lower M2 marker (Arg1 and
CD206) expression but significantly higher M1 marker (iNOS) expression and also had
higher expression levels of inflammatory cytokines IL1β and TNFα, although without
statistical significance (Figure 3.2B).
To exclude the possibility that reduced total TAMs and M2 marker expression in
emodin-treated breast cancer mice was the result of halted tumor growth instead of it
being the cause, we next investigated emodin’s effects on macrophages in tumors at the
time point when there was no difference in the size of the tumors between the two
groups. Emodin significantly reduced the number of macrophages in 4T1 tumors 26 days
post implantation while the tumor size was not different between the two groups at this
time point; moreover, emodin significantly reduced the fraction of macrophages positive
for transcription factors pSTAT6 and C/EBPβ (Figure 3.2C and D), indicating that
emodin indeed directly inhibited the macrophage infiltration and M2 polarization in the
tumors independent of tumor size.
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Furthermore, we isolated TAMs from 4T1 tumors at the experimental endpoint
and found that TAMs in emodin-treated mice had significantly decreased expression of
IRF4 compared to those in control mice (Figure 3.2E). IRF4 has previously been shown
to play a major role in macrophage M2 activation and is regulated by removal of H3K27
tri-methylation (H3K27m3) by histone demethylase JMJD3 (21,22). We found that
emodin significantly decreased the expression of JMJD3 in TAMs (Figure 3.2E).
Therefore, we further examined emodin’s effect on H3K27m3 marks using ChIP-qPCR
and found that emodin significantly increased H3K27m3 levels on the IRF4 promoter
(Figure 3.2F). Taken together, these results indicate that emodin inhibited M2 like
polarization in TAMs through epigenetically blocking IRF4, STAT6, and C/EBPβ
signaling pathways in the breast cancer TME.
Emodin inhibits macrophage response to tumor cell-derived soluble factors
Next, we examined the effects of emodin on the response of macrophages to
tumor cell derived factors. Peritoneal macrophages from C57BL/6 mice were treated with
EO771 TCM and gene expression was examined by qPCR. Emodin dose dependently
inhibited TCM-induced expression of Arg1 and transcription factors C/EBPβ and IRF4
(Figure 3.3A). Emodin also decreased the expression of CSFr1 (Figure 3.3A), a key
receptor on macrophages through which they are induced by tumor-secreted CSF1
towards M2-like activation (70,71). Moreover, emodin inhibited the expression of proangiogenic factors MMP2 and MMP9 (Figure 3.3A) (194,195). Interestingly, we also
found that TCM treatment increased expression of ICAM1 in macrophages and the effect
was dose dependently blocked by emodin, suggesting that emodin could interfere with
macrophage adhesion to tumor cells. In agreement with the in vivo data, TCM treatment
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increased the expression of JMJD3, and emodin significantly attenuated the increase
(Figure 14B). Both TCM and emodin had no effects on global levels of H3K27
methylation

(Figure 3.3C). However, TCM decreased H3K27m3 on the promoter of

Arg1, IRF4, and C/EBPβ but emodin treatment reversed the reduction (Figure 3.3D).
These results indicate that emodin epigenetically inhibits macrophage activation in
response to tumor-cell derived soluble factors.
Emodin increased T cell activation and decreased angiogenesis
TAMs substantially contribute to the immunosuppressive microenvironment in
tumors. Since emodin inhibited TAM infiltration and M2-like polarization, we
hypothesized that emodin treatment would lead to increased T cell activation in breast
tumors. T cells were detected in the draining lymph nodes of mice bearing 4T1 tumors
using flow cytometry. Emodin treated mice had increased activated CD4 + and CD8+ T
cells (Figure 3.4A). There was a similar trend of increased activated T cells in the tumors
of emodin treated mice (Figure 3.4B).We then isolated CD3 + cells from the tumors and
analyzed them using qPCR. T cells from emodin treated mice had a two-fold increase in
IFNγ expression compared to those from control mice (Figure 3.4C). Taken together,
these data indicate that emodin treatment led to increased T cell activation in breast
tumors.
Next we investigated whether or not emodin increased activated T cells in breast
tumors through its effects on TAMs. Peritoneal macrophages were pre-treated with
EO771 TCM with or without emodin for 24 h. Then the macrophages were incubated 1:1
with T cells stimulated with CD3/CD28 beads for 24 h. TCM treated macrophages
reduced expression of activation marker CD69 by 70% on CD4 T cells compared to
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control macrophages (Figure 3.4D); however, pre-treatment of macrophages with emodin
along with TCM completely blocked the suppression of T cell activation and even
increased CD69 expression on CD4 T cells above that of T cells co-cultured with control
macrophages. T cell proliferation was examined after 72 h by CSFE depletion analysis
and revealed that TCM and emodin co-treated macrophages restored T cell proliferation
which was suppressed by TCM only-treated macrophages (Figure 3.4E).
TAMs have also been shown to promote angiogenesis in breast tumors (100,101).
Therefore, we examined the effects of emodin on angiogenesis in tumors by staining
tumor sections with mouse endothelial antigen CD31 to detect microvessel density.
Emodin significantly decreased CD31 staining in EO771 tumors to almost 50% of that in
control tumors (Figure 3.4E). Taken together these data indicate that emodin was able to
increase T cell activation and suppress angiogenesis in breast cancer.
Emodin affected gene expression in breast cancer cells
Tumor cell-TAM interaction has been shown to be a complex feedback loop that
leads to a pro-tumor macrophage phenotype (85,196). Our results have shown that
emodin can inhibit the response of macrophages to tumor secreted signals, but it is
unknown if emodin could affect the ability of tumor cells to communicate with and
therefore train macrophages. EO771 and 4T1 cells were treated with emodin in vitro and
cell viability (LDH method) and proliferation (KI67 staining) was determined and gene
expression was detected. The results showed that emodin had low toxicity toward the two
cell lines used. There was only a slight effect on cell viability starting at 25µM (Figures
3.5A) and no significant effect on cell proliferation at concentrations less than 50 µM
(Figure 3.5B). We then examined the effect of emodin on tumor cell gene expression.
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Emodin significantly inhibited the expression macrophage chemoattractant and growth
factors CCL2, CSF1, and CSF2 in both 4T1 and EO771 cells (Figure 3.5C). Emodin
treatment also significantly inhibited tumor cell expression of Thy1 (Figure 3.5D), which
has been shown to help anchor macrophages to the tumor cells and supports juxtacrine
signaling (60). These results indicate that emodin could interfere with the ability of tumor
cells signal to, recruit, and polarize macrophages.
Emodin blocks macrophage-tumor cell interactions.
We examined if emodin could inhibit tumor cell induction of macrophage
migration. Conditioned medium was collected from tumor cells treated with various
concentrations of emodin, and its ability to induce macrophage migration as examined.
There was a decrease in macrophage migration toward the TCM collected from cells
treated with increasing concentrations of emodin (Figure 3.6A). These results suggest
that emodin inhibits the ability of breast cancer cells to attract macrophages.
Recent studies have shown that tumor cells can use juxtacrine signaling to
communicate with macrophages and induce them toward a pro-tumor phenotype
(60,65,98). We therefore examined the effects of emodin on tumor cell-macrophage
adhesion by pre-treating macrophages, tumor cells, or both with emodin. We found that
emodin treatment of either macrophages or tumor cells significantly inhibited the
adhesion of macrophages to a monolayer of tumor cells, and treatment of both
macrophages and tumor cells decreased the adhesion even further (Figure 3.6B). Taken
together, these data show that emodin inihibits breast cancer cell-macrophage adhesion
by acting on both cell types.
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3.4 DISCUSSION
Our data show that emodin significantly inhibited the growth of breast cancer by
modulating the tumor microenvironment (TME). Emodin inhibited tumor cellmacrophage interactions through blocking the response of macrophages to tumor signals
and by inhibiting the paracrine and juxtacrine signaling from tumor cells to macrophages.
Emodin treatment inhibited macrophage infiltration and M2- polarization by blocking
STAT6, C/EBPβ, and IRF4 signaling in macrophages. Emodin epigenetically regulated
macrophage polarization by increasing the amount of H3K27m3 on the promoters of
IRF4 and other M2 associated genes. Through its effects on TAMs, emodin effectively
increased T cell activation and inhibited angiogenesis in breast tumors. In addition,
emodin inhibited tumor cell-macrophage adhesion at least partially via suppressing Thy1
expression on tumor cells and ICAM1 expression on macrophages. Emodin also inhibited
tumor cell secretion of macrophage chemoattractants and growth factors CCL2, CSF1,
and CSF2. Taken together, these data show that emodin blocks the pro-tumor
feedforward loop between cancer cells and macrophages by targeting both cell types
(Figure 3.6C).
The majority of previous studies on emodin have been focused on emodin’s direct
toxicity to tumor cells (150,158,197). A few studies have also found that emodin could
inhibit tumor growth through inhibiting angiogenesis (125,198). In this study, we
administered emodin immediately following tumor cell implantation, before the tumor
cells could establish their microenvironment and found that emodin significantly
inhibited growth of the primary tumor. We used two well-established breast cancer cell
lines, EO771 and 4T1, and corresponding syngeneic mouse models. We found that
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emodin exhibited little or no direct toxicity towards either of the cell lines at
concentrations lower than 25 µM. As demonstrated in our previous study, 25 µM is the
highest plasma concentration of emodin we detected in vivo using an intraperitoneal dose
of 40mg/kg (133). Furthermore, emodin had no effect on tumor cell proliferation, as
shown by Ki67 staining, at doses less than 50 µM. Therefore, it is likely that emodin
inhibits tumor growth predominately through modulating the tumor microenvironment in
our study. Emodin decreased macrophage infiltration in the breast tumors and inhibited
TAM polarization by suppressing IRF4, STAT6 and C/EBPβ signaling. Also, we are the
first to report that emodin epigenetically regulated TAM polarization by inhibiting IRF4,
CEBPβ, and Arg1 expression through increasing H3K27m3 on their promoter regions,
likely by decreasing the expression of H3K27 demethylase JMJD3.
Emodin treatment increased T cell activation in tumors. Emodin has previously
been reported to induce apoptosis in human T cells (199), and we found similar results
with direct emodin treatment of T cells isolated from spleens of mice (Figure 3.7).
Therefore, emodin likely activates T cells indirectly through inhibiting TAM-mediated
immune suppression. TCM treated macrophages significantly inhibited T cell activation
and proliferation; however, emodin treatment abrogated the suppressive ability of TCM
treated macrophages. The reduced angiogenesis in tumors of emodin-treated mice may be
due to several mechanisms. Emodin has previously been shown to inhibit tumor
angiogenesis by inhibiting tumor cell production of MMPs and by blocking VEGF
signaling (165-167). In addition, emodin could directly target endothelial cells to inhibit
proliferation and vessel formation (169,170). However, we found that emodin might be
able to inhibit angiogenesis through targeting TAMs. Emodin decreased breast tumor

70

vascularity and inhibited macrophage expression of MMP2 and MMP9 in response to
tumor cell derived soluble factors.
Although emodin did not cause direct cytotoxicity to breast cancer cells at lower
than 25 µM concentrations, it did significantly inhibit the ability of tumor cells to attract
and polarize macrophages through blocking the secretion of MCP1 and CSF1, two
chemokines that play important roles in the TME (98). In addition, emodin reduced Arg1,
IRF4, and C/EBPβ expression in TAMs, which promote the immunosuppressive
phenotype (182,200,201). Moreover, emodin reduced TAM expression of CSF1r. Tumor
derived soluble factors decreased the expression of transcription inhibitory mark
H3K27m3 at the promoters of M2 associated genes (IRF4, Arg1, CEBPβ, and YM1).
Emodin prevented the loss of H3K27m3 likely by inhibiting the TCM induced expression
of JMJD3. Emodin also significantly inhibited the ability of tumor cells to attract and
polarize macrophages through blocking the secretion of chemoattractant CCL2 and
growth factors CSF1 and CSF2. Therefore, our results indicate that emodin is able to
inhibit both macrophage response to tumor derived signals and tumor cell expression of
signaling molecules.
Juxtacrine signaling between macrophages and breast cancer cells has been shown
to be important for tumor growth. Expression of adhesion protein CD90, which can
interact with integrins on monocytes/macrophages, can greatly enhance breast cancer
growth (22). CD90hi human breast cancer cells formed significantly larger and more
aggressive tumors than CD90lo cells when injected into the mammary fat pad of Nude
mice. Previous studies have shown that emodin has potential to block cell-cell
interactions by inhibiting the expression or function of adhesion molecules on the surface
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of cells. Liu and colleagues reported that emodin treatment could dose dependently
reduce adhesion of THP-1 monocytes to fibroblast monolayers (136). Similarly emodin
treatment inhibited the expression of cell surface adhesion proteins ICAM1, VCAM1,
and ELAM1 in human endothelial cells (203). In agreement with these studies, our data
shows that emodin is able to block tumor cell-macrophage adhesion. Emodin decreased
expression of cell adhesion proteins CD90 (THY-1) on tumor cells and ICAM-1 on
macrophages.
In summary our results show that emodin emodin acts on both breast cancer cells
and TAMs and thus ameliorates the immunosuppressive Emodin inhibits tumor cell
recruitment and education of macrophages; and transcriptionally and epigenetically
inhibits the response of macrophages to tumor-secreted factors. The reduction of M2-like
macrophage numbers led to increased T cell activity in tumors, reduced angiogenesis, and
reduced tumor growth. Therefore, emodin may be developed as a potent therapy for
breast cancer
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Tables
Table 3.1 Primers for qPCR
Primers
CD86
CEBPB
CSF1
CSF2
IFNg
JMJD3
THY-1

Forward
GCACGTCTAAGCAAGGTCAC
CAAGCTGAGCGACGAGTACA
CACCTTCTCCAGTGTGCTGA
CAAAGAAGCCCTGAACCTCCTG
GGAACTGGCAAAAGGATGGTGA
TCGCGGTACATGAGCACTAT
TGAACCAAAACCTTCGCCTG
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Reverse
CATATGCCACACACCATCCG
AGCTGCTCCACCTTCTTCTG
GGAGTCCATAGGGAGGAAGC
ATTGCCCCGTAGACCCTGCTC
TTGTTGCTGATGGCCTGATTGT
ATCCACACAAGGTCTCCAGG
AGTAGTCGCCCTCATCCTTG

EO771

1500

Emodin

**

1000

**

*
**

500

*** ***
0
16

19

22

25

4T1
4T1

1500

Control

Tumor Volume (mm 3)

A.

Tumor Volume (mm3)

Figures

28

31

1000

*
500

0

34

***
* *

Days post tumor cell injection

19

23

26

29

32

35

37

40

Days post tumor cell implantation

B.
Control
Emodin
C.

2.0

Tumor weight (g)

Tumor weight (g)

2.5

*

2.0
1.5
1.0
0.5

*

1.5
1.0
0.5
0.0

0.0

Control

Control

Emodin

Emodin

Figure 3.1 Emodin inhibits growth of breast tumors. C57BL/6 (n=7 for control, n= 8
for emodin group) or BALB/c (n=9 for control, n=7 for emodin group) were injected with
2x105 EO771 or 4T1 cells respectively. Emodin treatment (40 mg/kg IP once daily)
began on day 1 following tumor injection of tumor cells. A. Tumor size was measured
with calipers and volume was calculated using the following formula: V (mm3) = L x
W2/2. B. Representative image of tumors. C. Weight of tumors. *p<0.05, **p<0.01,
***p<0.001.
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Figure 3.2 Emodin inhibits macrophage infiltration into tumors and activation. A.
EO771 tumors were embedded in OCT (n=5). Tumors were cut in 8 µm sections and
stained for F4/80. Sections were imaged (200x, 10 fields per section) and the number of
positive cells was manually counted. Results are shown as means ± S.E. B. F4/80+ cells
were isolated from the EO771 tumors of C57BL/6 mice (n=5). Gene expression was
detected using RT-qPCR. C. and D. 4T1 tumors from mice were collected 26 days post
injection and embedded in OCT (n=6 for control, n=5 for emodin group). Tumors were
cut in 8 µm sections and stained for F4/80 and pSTAT6 or C/EBPβ. Sections were
imaged (200x, 5 fields per section) and the number of positive cells was manually
counted. Results are shown as means ± S.E. E. F4/80+ TAMs were isolated from 4T1
tumors using magnetic beads at the experimental end point. Gene expression (n=9 for
control, n=7 for emodin group) was detected using RT-qPCR. F. A ChIP assay was used
to detect H3K27m3 levels on the promoters of IRF4 and C/EBPβ (n=8 for control, n=6
for emodin group). Results are shown as means ± S.E. *p<0.05, ***p<0.001
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Figure 3.3 Emodin inhibits macrophage response to tumor cell secreted factors.
Peritoneal macrophages were stimulated with EO771 TCM with or without emodin for
24 h. A. and B. Gene expression was detected using RT-qPCR, n=3. Results shown as
means ± S.E of one of two independent experiments. C. Histones were extracted from the
macrophages and histone modifications were detected using an EpiQuick histone
modification kit, n=3. D. Gene specific H3K27m3 levels were detected using a ChIP
assay. Results shown as means ± S.E. of one of two independent experiments, n=3.
*p<0.05, **p<0.01, ***p<0.001

77

Lymph node
A.

Control

Emodin

Percent
Percent

CD4

25
20
15

**

10

CD8

5

p=0.057

0

CD4++ CD4
CD4++CD25
CD8+++ CD8
CD8++CD25+
CD4
CD8
CD25+
CD25+

CD25

B.

C.

Tumor T cells

Tumor
T cell-IFN 

3

Relative Expression

Cells (x103)/mg

6

4

2

25

D

D
8+

C

2

1

0

Control

C

C

CD8+
CD25+

C

D
8

25

D

CD4+ CD8+
CD25+

D
4+

C

CD4+

C

D
4

0

**

D.

E.
T cell activation

20000

150

Percent control

30000

MFI CD69

Cell number

Unstained
Control Mφ
TCM Mφ
TCM-Em Mφ

***

***

10000

0

Con

TCM

Control

T cell proliferation

***

***

100

50

0

TCM-Em

Con

CD69

F.

Emodin

TCM

TCM-Em

Emodin

Fold change

2.0

CD31

Tumor CD31

1.5
1.0

*

0.5
0.0

Control

78
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Figure 3.4 Emodin inhibits macrophage suppression of T cell activation and support
of angiogenesis. A. and B. The draining lymph node and tumors from mice bearing 4T1
tumors (n=9 for control, n=7 for emodin group) was collected at experimental end point.
A single cell suspension was made, and the cells were stained with CD3, CD4 or CD8,
and CD25 to detect activated T cells. Cells were analyzed using flow cytometry. Right
panel shows results as means ± S.E. C. CD3+ T cells were isolated from the draining
lymph node of mice bearing 4T1 tumors 6 weeks after tumor cell injections. Gene
expression was detected using RT-qPCR. D. Peritoneal macrophages were treated with
EO771 TCM with or without emodin for 24 h. They were then washed and co-cultured
with T cells isolated from the spleens of mice and stimulated with CD3/CD20
microbeads at a ratio of 1:1, n=3. After 24 h, the T cells were collected and stained with
CD3, CD4, and CD69 and analyzed using flow cytometry. Left panel shows
representative flow cytometry results. Right panel shows results as means ± S.E. E.
Macrophages were pre-treated with TCM with or without emodin for 24 h. Then they
were washed and co-cultured with T cells labeled with CSFE and stimulated with
CD3/CD20 microbeads. After 72 h, the cells were collected and stained for CD3 and
CD4, and CSFE depletion was detected as a measure of proliferation. Results are shown
as means ± S.E. of one of two independent experiments. F. EO771 tumors were collected
from mice 5 weeks post injection and embedded in OCT. The tumors (n=5) were cut into
8 μm thick sections, stained with CD31, and imaged (10 fields per section at 200x).
Images were quantified using ImagePro plus by calculating the IOD for CD31 positive
areas. Results (right panel) are shown as means ± S.E. *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.5 Emodin inhibits tumor cell recruitment of macrophages. Tumor cells were
cultured with various concentrations of emodin (0-100 µM) for 24-48 h. A. Cell viability
was detected using an LDH assay, n=4. Results are shown as means ± S.E. for one of two
independent experiments B. Tumor cells were stained for Ki67 (n=3) after 24 h culture.
Cells were then analyzed using flow cytometry. Results are shown as means ± S.E. C.
and D. After 24 h, gene expression was detected using RT-qPCR (n=3). Results shown
as means ± S.E. of one of two independent experiments. *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.6 Emodin inhibits macrophage adhesion to tumor cells. A. 4T1 cells were
treated with varying concentrations of emodin for 24 h. The cells were then washed and
cultured in fresh medium for 48 h. Conditioned medium was collected from the cells and
placed in the bottom chamber of transwell inserts. Peritoneal macrophages were placed in
the top and incubated for 4 h. The cells were then fixed and the membranes were
mounted onto slides and imaged (200x, 5 fields per membrane), n=3. The number of cells
that migrated to the bottom chamber were counted. Results shown as means ± S.E. of one
of two independent experiments. B. Peritoneal macrophages and/or 4T1 cells were
treated with emodin for 24 h. Then the macrophages were collected and seeded onto 4T1
cell monolayers, n=3. After 1 h, non-adherent cells were washed away and the remaining
cells were collected and counted. Cells were then stained with F4/80 and analyzed using
flow cytometry. Results shown as means ± S.E. C. Illustration showing how emodin
interferes with tumor cell-macrophage interactions. Red “X”s represent emodin’s
functions. *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.7 Emodin induces T cell apoptosis. CD3+ cells were isolated from spleens of
mice using magnetic beads. The T cells were then incubated with emodin for 24 h in
DMEM+10% FBS plus IL2 (10 ng/ml). The cells were then washed and stained for
Propidium Iodide and Annexin V.
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CHAPTER 4
CONCLUSIONS AND FUTURE PERSPECTIVES
The discovery of the substantial role that macrophages play in a variety of
diseases, especially cancer, has opened up new avenues of therapy, for these diseases.
However, the diversity and plasticity of macrophages make it challenging to develop
therapies to target macrophages within different pathologies. Macrophages display a
variety of different phenotypes even within the same pathology depending on their
location within the tissue or the stage of the disease (37,194,204). In the typical wound
healing response, M1 macrophages dominate early, but after 1-2 weeks M2 macrophage
become the dominate phenotype (205). Similar phenotype switching is seen in cancers
with pro-inflammatory macrophages dominating early but eventually the majority of
macrophages adopt an M2-like phenotype. Furthermore, macrophage phenotype varies
upon location within tumors (55,79). M2-like TAMs tend to localize to hypoxic regions
of tumors while more M1-like TAMs can be found in normoxic tumor areas. Varying
populations of monocytes/macrophages could also be differentially recruited to the
primary tumor or sites of metastasis (79). Complicating matters further, macrophage
activation is regulated by many different signaling pathways which co-ordinate to finetune their response to environmental signals (16,173). Therefore, herb derived
compounds which are capable of targeting multiple pathways have been receiving
increasing attention for use alongside tradition therapies (74,120,121). The value of using
combination therapies to target/manipulate the immune component of diseases is
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becoming evident, particularly in cancers (185,206,207). Emodin is an active ingredient
of several Chinese herbs which have been used for centuries to treat inflammatory
disease (125). Many studies have been performed on emodin investigating its potent antiinflammatory and anti-cancer mechanisms; however, its specific mechanisms of action
have not been well elucidated. Emodin is able to inhibit the activity of a variety of
kinases and transcription factors including: CK2, HER2/neu, JAK, STAT3, NFκB, ERK,
PI3K, P38 (125). Emodin has also been reported to have varying effects on the same
signaling molecules such as PPARγ, TGFβ, IL4, and TNFα (125,142,145-147,208). One
explanation for these findings could be the use of different experimental models. This
would indicate that emodin’s function on inflammatory cells could be dependent on the
environment of the cells. However, most of the studies performed on emodin have only
evaluated its effects under a narrow range of conditions. Therefore, our attempt to better
characterize emodin’s effects on macrophages and its ability to be used as a therapy for a
macrophage-driven pathology is a first of the kind.
Microarray analysis of macrophages stimulated with M1 or M2 stimulants
confirmed that emodin is able to inhibit both directions of macrophage activation
(Figures 2.2-2.4). Analysis of the dataset with Ingenuity IPA software was unable to
identify emodin’s direct target with high probability, but instead provided many different
possible proteins as direct targets of emodin. These results lend support to the hypothesis
that emodin can inhibit many different signaling pathways dependent on environment of
the macrophages. Emodin inhibited STAT1, NFκB, and IRF5 signaling in response to
LPS/IFNγ stimulation, and STAT6 and IRF4 signaling in response to IL4 stimulation
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(Figure 2.7). These results showed for the first time emodin’s ability to regulate the
antagonistic IRF4 and IRF5 signaling pathways.
Furthermore, our results revealed that emodin could epigenetically regulate
macrophage activation by regulating gene specific methylation and acetylation of histone
3 lysine 27 (Figure 2.8). Previous studies have hinted that emodin could epigenetically
regulate cell responses. Emodin was reported to increase genome wide H3K27m3 in
bladder cancer cells in which H3K27m3 marks are repressed (209). Another study found
that emodin could inhibit the expression and activity of HDAC1 in synoviocytes (137).
However, emodin’s effects on gene specific histone modifications in macrophages have
not been previously reported. Our results also showed for the first time the ability of
emodin to regulate macrophage memory. The ability of cytokines or other environmental
stimuli to alter macrophage’s response to future stimuli is only recently becoming
understood (210,211). Cytokines can alter histone modifications, such as H3K4m3 or
H3K27ac, to prime genes for increased expression upon a second stimulation (178,212).
Emodin was able to effectively block this effect likely through the regulation of histone
modifications. These findings demonstrate novel functions of emodin and, while not
identifying which specific proteins emodin targets, further elucidate the ability of emodin
to modulate macrophage activation by targeting multiple transcriptional and epigenetic
signaling pathways. Emodin is able to push the phenotype of cells from the extremes of
M1 or M2 toward a more central state, which was especially evident by emodin’s ability
to reciprocally regulate a subset of genes under the two different conditions (Table 2.4).
The majority of studies on emodin as a cancer therapy focused on its direct
toxicity toward cancer cells. A few studies have reported that emodin could inhibit
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angiogenesis by preventing the release of angiogenic factors from tumor cells. Our results
revealed that emodin is able to inhibit the growth of breast tumors in mice at a dose
which showed little to no direct cytotoxicity towards the tumor cells (Figure 3.1 and 3.5).
Emodin treatment shifted the phenotype of TAMs from an M2-like state toward an M1
phenotype which inhibited their immunosuppressive potential (Figure 3.2 and 3.4). Our
results demonstrated for the first time emodin’s ability to inhibit tumor cell-macrophage
interactions by blocking both the ability of tumor cells to signal to macrophages and
macrophages’ response to tumor cells (Figure 3.3 and 3.5). Moreover, emodin was able
to inhibit tumor cell-macrophage adhesion (Figure 3.6). These results demonstrate a
novel mechanism by which emodin inhibits tumor growth.
There have been many obstacles for the development of cancer immunotherapies,
including the ability of tumors to adapt to the immune attack, known as immunoeditting,
and the ability of tumors to train stromal cells to create an immunosuppressive
environment (93,213). Further, the development of TAM targeting therapies has been
complicated by the diversity of TAM phenotypes within tumors (67,79,213). Emodin’s
ability to interfere with the communication between tumor cells and TAMs by a variety
of mechanisms as demonstrated in our study confers it great therapeutic potential to
overcome these obstacles. Experimental studies have demonstrated that optimal
effectiveness of immunotherapies likely requires the combination of treatments that
activate T cells and those that reduce the immunosuppressive microenvironment of
tumors (185,213-215). The properties of emodin demonstrated in our studies hold great
promise for emodin to be used to complement current T cell activating therapies, such as
checkpoint inhibitors.

86

Our results further indicate that emodin treatment alone is most beneficial when it
occurs in the early stages of tumor progression prior to the establishment of the TME.
Emodin’s properties give it strong potential as a therapy to block breast cancer metastasis
as well as inhibit recurrence following primary tumor removal. Finally, the role of
macrophage memory in the progression of pathologies is only recently becoming
appreciated (216,217). Emodin’s ability to regulate macrophage memory suggests that it
can also be developed as a therapy to block maladaptive macrophage training.
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